一站式复合技术治疗冠状动脉多支病变的安全性和有效性研究
|
摘要
中文摘要(第一部分)：一站式复合技术再血管化治疗冠状动脉多支病变的近中期临床结果
目的：
一站式复合技术融合了经皮冠状动脉介入治疗(Percutaneous coronary intervention, PCI)和微创冠状动脉旁路移植术(Minimally invasive direct coronary artery bypass, MIDCAB)的优势,在配备有影像学设备的“复合”手术室内对病人实施完全再血管化,并进行实时影像学评价。本研究旨在总结一站式复合技术血运重建治疗冠状动脉多支病变的初步临床经验,并分析一站式复合技术血运重建的安全性和临床应用价值。
方法：
自2007年6月至2009年12月,连续有104例患者在我院接受一站式复合技术血运重建。冠状动脉病变支数平均2.4支／例。首先经胸骨下端小切口在不停跳状态下行LIMA至LAD旁路移植术,即刻冠状动脉造影证实LIMA-LAD通畅后同期对其它冠状动脉病变靶血管行PCI治疗。对围术期抗凝抗血小板方案进行改良如下：围术期持续应用阿司匹林；MIDCAB术后即刻冠状动脉造影证实血运重建满意后给予负荷剂量波立维300mg,术后予维持剂量75mg／天应用12个月。
结果：
共有103例(99.0%)患者成功进行一站式复合技术血运重建,1例(1.0%)患者在对第一钝缘支行PCI治疗时,因钝缘支夹层形成且血流动力学不稳定遂在一站式复合手术室内转为体外循环下CABG.术中冠状动脉造影示4例(3.8%)患者LIMA-LAD吻合不满意,立即再次开胸手术矫正。PCI治疗冠状动脉靶病变188处,平均1.8±0.9支／人；其中12处(6.4%)靶病变仅行PTCA,其余病变均置入支架,共置入191枚DES,3枚BMS。PCI即刻造影成功率为98.4%。术后因呼吸衰竭死亡1例(1.0%),急性肺栓塞1例(1.0%),胸腔积液5例(4.9%),出现新发房颤12例(11.5%)。术后30天内无心肌梗死、因出血而再手术、急性肾功能衰竭、脑血管意外或再血管化等发生。术后平均随访15.0±8.5月,随访期间无死亡、心肌梗死或脑血管意外等发生。术后1年30例(29.4%)患者行冠状动脉造影复查,3例(2.9%)行冠状动脉多层螺旋CT检查,所有LIMA桥血管均证实通畅,未发现支架内狭窄或支架内血栓形成。1例(1.0%)患者在术后1年的冠状动脉造影随访时因回旋支近端新发病变而再次接受PCI再血管化。1例(1.0%)患者心绞痛复发,现药物治疗。
结论：
一站式复合技术再血管化治疗冠状动脉多支病变安全可行。
中文摘要(第二部分)：一站式复合技术与非体外循环冠状动脉旁路移植术治疗冠状动脉多支病变的对比研究
目的：
非体外循环冠状动脉旁路移植术(Off-pump coronary artery bypass, OPCAB)是目前最为常用也是较为成熟的外科血运重建微创术式。本研究旨在比较一站式复合技术与OPCAB治疗冠状动脉多支病变患者的近期临床结果,并评价一站式复合技术治疗冠状动脉多支病变高危患者的临床应用价值。
方法：
自2007年6月至2008年12月,共有52例患者在我院接受一站式复合技术冠状动脉血运重建。同期360例冠状动脉多支病变患者行单纯OPCAB,应用倾向性评分匹配(Propensity score matching)的统计方法抽取52例OPCAB患者与一站式复合技术组患者进行1：1配对。研究终点是两组患者院内临床结果和随访期间的免于主要心脏或脑血管不良事件(Major adverse cardiac or cerebrovascular events, MACCE)发生的生存率。
结果：
两组之间患者基线特征无明显差异。两组院内均无MACCE发生,主要并发症发生率之间无显著差异。一站式复合技术组的ICU滞留时间为(33.3±28.4)小时,呼吸机辅助时间为(11.5±6.9)小时,术后平均住院(8.1±1.7)天,均相应的少于OPCAB组(分别为(49.3±39.0)小时,P=0.03；(18.2±18.2)小时,P=0.0003；(9.1±3.1)天,P=0.047)。一站式复合技术组术后失血量为(860±460)mL,显著少于OPCAB组((1108±59)mL,P=0.02),需要输血的比例(34.6%)显著低于OPCAB组(55.8%,P=0.03)。但一站式复合技术再血管化耗时较长,费用高于OPCAB组。平均随访15.4±5.2个月,一站式复合技术组和OPCAB组之间实际生存率分别为100%和94.2%(Log-rank P=0.11),两组免于MACCE发生的生存率分别为96.2%和90.4%(Log-rank P=0.84),两组之间差异均无统计学意义。
结论：
与OPCAB相比较,一站式复合技术再血管化可减少术后出血量和血液制品的使用,促进术后尽快恢复。近期随访结果显示一站式复合技术可以达到与传统OPCAB相近的临床结果。
中文摘要(第三部分)：一站式复合技术与经皮冠状动脉介入治疗冠状动脉多支病变的对比研究
目的：
PCI是冠状动脉再血管化最为常用的手段。本研究旨在比较一站式复合技术与常规PCI治疗冠状动脉多支病变的近期临床结果,并进一步评价一站式复合技术的临床应用价值。
方法：
自2007年6月至2008年12月,共有52例患者在我院接受一站式复合技术冠状动脉血运重建。同期399例冠状动脉多支病变患者行PCI治疗,应用倾向性评分匹配(Propensity score matching)的统计方法抽取52例OPCAB患者与一站式复合技术组患者进行1：1配对。研究终点是两组患者院内临床结果和随访期间的免于MACCE发生的生存率。
结果：
匹配后两组患者的大部分术前基线资料无显著的统计学差异。两组患者院内均无死亡、围术期心肌梗死、脑卒中、支架内血栓或再次再血管化等发生。一站式复合技术组中有6例(11.5%)为无保护左主干病变。一站式复合技术组前降支系统使用的支架数量(复合技术组0.1±0.3枚／人,PCI组1.1±0.4枚／人,P<0.01)、平均置入的支架数(复合技术组1.7±0.9枚／人,PCI组2.6±0.7枚／人,P<0.001)以及置入支架的长度(复合技术组34.0±20.1mm,PCI组42.2±19.9mm,P=0.04)均显著低于PCI组。一站式复合技术组患者的完全再血管化程度(定义为直径在2.25mm以上且狭窄≥70%的靶血管均得到血运重建)为96.2%,显著高于PCI组(67.3%,P=0.0001)。两组支架置入成功率和院内总费用无显著差异。术后平均随访11.2±4.0个月,两组均无死亡、心梗或脑卒中等不良事件发生,一站式复合技术组1例(1.9%)患者因新发病变而再次血管化,1例(1.9%)患者因首次未完全再血管化而再次行PCI。PCI组有6例(11.5%)患者再次住院行PCI治疗。一站式复合技术组免于MACCE的生存率为96.2%,显著高于PCI组(88.0%,Log-rank P=0.001),差异有统计学意义。
结论：
一站式复合技术再血管化可以安全有效地用于冠状动脉多支病变和无保护左主干病变的治疗。与传统PCI比较,一站式复合技术再血管化可以减少支架的使用数量,提高完全再血管化程度,降低术后近期的MACCE发生率。
中文摘要(第四部分)：应用血小板聚集率评价一站式复合技术血运重建改良抗血小板方案的有效性研究
目的：
一站式复合技术融合了PCI和MIDCAB的优势,可以在配备有影像学设备和心脏外科设备的“复合”手术室内对病人完全再血管化,并进行实时影像学评价。一站式复合技术的出现,为一些具备传统手术高危因素的多支病变患者提供了一种更个性化的治疗选择,但是PCI／支架置入术后必需的抗凝抗血小板治疗与外科术后出血之间的矛盾仍然是该技术临床应用面临的难题。本研究以传统PCI的常规抗凝抗血小板治疗措施为对照,通过评价本研究所采用的抗凝抗血小板策略下围术期血小板活性的变化,评价该抗凝抗血小板治疗措施的有效性。
方法：
自2008年9月至2009年2月,连续有23例冠状动脉多支病变患者(复合技术组)接受一站式复合技术血运重建,选择同期接受传统PCI／支架置入治疗的20例多支病变患者为对照(PCI组)。PCI组患者围术期常规服用阿司匹林300mg／天,术前给予波立维负荷剂量(300mg),此后予75mg／天维持1年。该改良的抗血小板治疗方案为围术期持续应用阿司匹林；MIDCAB术后即刻冠状动脉造影证实血运重建满意后给予负荷剂量波立维300mg,术后予维持剂量75mg／天应用12个月。分别在术前、术后2小时、术后24小时和72小时取血标本,采用光学法血小板聚集实验(Platelet aggregation test, PAgT)检测血小板活性变化。分别通过花生四烯酸(Arachidonic acid, AA)(终浓度为0.5mmol／L)诱导的PAgT和二磷酸腺苷(Adenosine diphosphate, ADP)(终浓度为10μmol／L)诱导的PAgT反映阿司匹林和波立维的血小板抑制效果。
结果：
复合技术组术后24小时血小板数量(160×103／μL)显著低于PCI组(207×103／μL,P=0.0018)。PCI组AA和ADP诱导的血小板聚集率在支架置入前后无明显变化。复合技术组术后24小时AA诱导的血小板聚集率为5.4%,显著高于术前基线值(4.4%,P=0.0079),也显著高于同时期PCI组AA诱导的血小板聚集率(3.5%,P=0.0023)。复合技术组术前ADP诱导的血小板聚集率为67.3%,显著高于同时期的PCI组(53.0%,P=0.011),此后逐渐降低,并于术后2小时和24小时达到与PCI组相似的血小板抑制程度。围术期无支架内血栓形成、因出血再次手术或大量出血等不良事件发生,两组30天内均无死亡、心肌梗死或再血管化等发生。
结论：
本研究的改良抗凝抗血小板方案在围术期持续应用阿司匹林,并在术中PCI之前应用负荷剂量波立维。血小板聚集率变化显示,该方案在术后早期即可达到与常规PCI抗血小板治疗方案相似血小板抑制效果。因此,该改良的抗凝抗血小板方案可安全有效的应用于一站式复合技术血运重建。
ABSTRACT (PART ONE): "One-Stop" Hybrid Coronary Revascularization for Multivessel Coronary Artery Disease with a Modified Antiplatelet Protocol:early and mid-term clinical outcomes
Objective:
"One-stop" hybrid coronary artery revascularization combines minimally invasive direct coronary artery bypass grafting (MIDCAB) and percutaneous coronary intervention (PCI) simultaneously in a single, enhanced operating suite. This study sought to investigate the early and mid-term clinical outcomes of this one-stop hybrid approach with a modified antiplatelet protocol.
Materials and Methods:
From June 2007 to December 2009,104 consecutive patients were planned to undergo one-stop hybrid coronary revascularization. MIDCAB was first performed to anastomosis the left internal mammary artery (LIMA) to the left anterior descending coronary artery (LAD) through lower partial ministernotomy. LIMA-LAD graft patency was then confirmed by coronary angiography. Catheter-based interventions on non-LAD lesions were then completed in the same setting. The modified antiplatelet regimen included perioperative aspirin; clopidogrel was routinely discontinued 7 days or more before operation, and then administered intraoperatively with a 300-mg loading dose, followed by a maintenance dose of 75 mg/day for 12 months.
Results:
One-stop hybrid procedure was successfully carried out in 103 (99.0%) patients. Conversion to conventional on-pump coronary artery bypass grafting (CABG) was required in 1 (1.0%) patient. Four major defects (3.8%) were found in the LIMA grafts and were immediately repaired. A total of 188 lesions were treated by PCI, mean number of lesions treated was 1.8±0.9 per patient. Angiographic success of PCI, based on visual analysis, was obtained in 185 of 188 lesions (98.4%). Balloon angiography alone was used in 12 lesions.191 drug-eluting stents (DES) and 3 bare-mental stents (BMS) were implanted. Angiographic success of stents was 100%. There was 1 (1.0%) deaths within 30 days after operation. One patient (1.0%) developed pulmonary thromboembolism, pleural effusion in 5 (4.9%) patients, and transient atrial fibrillation in 12 (11.5%) patients. All the 102 patients survived the follow-up period of 15.0±8.5 months. No deaths, myocardial infarctions, strokes, recurrent angina, severe bleeding, or stent thrombosis occurred. Thirty patients (29.4%) underwent follow-up coronary angiography and 3 patients (2.9%) underwent 64-slice computed tomography. All LITA grafts were confirmed patent. Only one patient (1.0%) underwent repeat revascularization at the 1-year follow-up angiogram.
Conclusions:
One-stop hybrid coronary revascularization provides a feasible and safe alternative for selected patients with multivessel disease, especially for those at high risk for conventional strategies.
ABSTRACT (PART TWO): Comparison of one-stop hybrid coronary revascularization and off-pump coronary artery bypass in the treatment of multivessel coronary artery disease: a propensity score matching analysis
Objectives:
OPCAB has been widely used as an alternative for the conventional on-pump coronary artery bypass. This study sought to compare the early and short-term clinical outcomes of one-stop hybrid coronary revascularization with those in a matched subset of patients undergoing OPCAB.
Materials and Methods:
From June 2007 to December 2008,52 consecutive patients underwent planned one-stop hybrid revascularization in our institution. By using propensity score matching method, a matched group of 52 patients were selected from a cohort of 360 patients who underwent conventional OPCAB via median sternotomy in our institution during the same period. We compared the in-hospital clinical outcomes and freedom from major adverse cardiac or cerebrovascular events (MACCEs) at follow-up period.
Results:
The baseline characteristics were similar between the two groups. Patients in the hybrid group required shorter intubation times ((11.5±6.9) hours versus 18.2±18.2, P=0.03), shorter lengths of stay in ICU ((33.3±28.4) hours versus (49.3±39.0) hours, P=0.003), less stay in hospital after operation ((8.1±1.7) days versus (9.1±3.1) days, P=0.047). Moreover, the one-stop hybrid group also showed significant reduction in total blood loss ((860±460) mL versus (1108±596) mL, P=0.02) and need of blood transfusion (34.6%versus 55.8%, P=0.03) than the OPCAB group. The in-hospital postoperative major complications were of no significant difference between the two groups. During a mean follow-up of 15.4±5.2 months, the hybrid group showed comparable with the OPCAB group in actual survival (100%versus 94.2%, Log-rank P=0.11) and MACCE-freesurvival (96.2%versus 90.4%, Log-rank P=0.84).
Conclusions:
The one-stop hybrid coronary revascularization shortens patient postoperative recovery, and shows superior in-hospital outcomes and noninferior short-term outcomes compared with OPCAB.
ABSTRACT (PART THREE): Comparison of one-stop hybrid coronary revascularization and percutaneous coronary intervention for the treatment of multivessel coronary artery disease: a propensity score matching analysis
Objectives:
PCI is the most commonly used intervention for coronary artery disease. This study compared one-stop hybrid approach and PCI for treating patients with multivessel or left main coronary artery disease (or both).
Materials and Methods:
From June 2007 to December 2008,52 consecutive patients underwent planned one-stop hybrid revascularization in our institution. By using propensity score matching method, a matched group of 52 patients were selected from a cohort of 399 patients who underwent conventional PCI in our institution during the same period. We compared the in-hospital clinical outcomes and freedom from MACCE at follow-up period.
Results:
Most baseline characteristics were similar between the two groups. No MACCE occurred during the in-hospital period. There were 6 patients (11.5%) with both multivessel and left main coronary artery disease in the one-stop hybrid group. Patients in the hybrid group required less stents implantation in left anterior descending (LAD) artery (0.1±0.3 versus 1.1±0.4, P<0.01) and less stents used per patient (1.7±0.9 versus 2.6±0.7, P<0.001), but achieved more complete revascularization (defined as residual restenosis less than 70%in vessels diameter more than 2.25mm) (96.2%versus 67.3%, P=0.0001). Average total stent length was 34.0±20.1 mm in the one-stop hybrid group versus 42.2±19.9 mm in PCI group (P =0.04). There were no significant differences in success rate of stent implantation and total in-hospital costs between this two groups. During a mean follow-up of (11.2±4.0) months, the hybrid group showed higher MACCE-free survival (96.2%versus 88.0%, Log-rank P=0.001) than the PCI group.
Conclusions:
One-stop hybrid revascularization is a safe and effective alternative for patients with multivessel and/or left main coronary artery disease. Compared with PCI, one-stop hybrid strategy could reduce the number of stent implantation, achieve more complete revascularization and result in greater clinical benefits at short-term follow-up.
ABSTRACT (PART FOUR): Evaluation of antiplatelet effects of a modified protocol by platelet aggregation in patients undergoing "one-stop" hybrid coronary revascularization
Objectives:
"One-stop" hybrid coronary revascularization has emerged to be a reliable and attractive alternative for selected patients with multivessel coronary artery disease. However, the optimal antiplatelet regimen of the one-stop hybrid procedure still remains controversial. We modified the antiplatelet protocol in order to reduce the risk of perioperative bleeding and maximally inhibit platelet activity. This study sought to investigate whether the inhibition of platelet activity by this modified antiplatelet protocol is comparable with the conventional protocol widely used and recommended in percutaneous coronary interventions (PCI).
Materials and Methods:
From September 2008 to February 2009,23 patients undergoing one-stop hybrid procedure and 20 patients undergoing conventional PCI with stenting were enrolled in this prospective study. The modified antiplatelet protocol included perioperative use of aspirin; clopidogrel was administered immediately before PCI with a 300-mg loading dose, followed by a maintenance dose of 75 mg/day for 12 months. Blood samples were obtained before the operation and 2 hours, day 1 and day 3 after operation. Platelet aggregation was induced with:1) arachidonic acid (AA) (final concentration 0.5 mmol/L) to assess the efficacy of aspirin; 2) adenosine diphosphate (ADP) (final concentration 10μmol/L) to assess the specific efficacy of clopidogrel.
Results:
Platelet counts were statistically lower in the hybrid group than in the PCI control group (160×103/μL versus 207×103/μL, P=0.0018) on day 1 after operation. AA-induced platelet aggregation increased significantly in the one-stop hybrid group in comparison with the preoperative baseline values (5.4%versus 4.4%, P=0.0079) and the PCI control group (5.4%versus 3.5%, P=0.0023) on day 1 after operation. ADP-induced platelet aggregation gradually decreased in the hybrid group, and achieved similar platelet inhibition with the PCI group on 2 hours and day 1 after operation. No major adverse clinical events such as death, perioperative myocardial infarction, stent thrombosis, or reoperation for bleeding occurred in both groups within 30 days after procedure.
Conclusions:
This study demonstrates that our modified antiplatelet therapy can sufficiently inhibit platelet activity similarly as the conventional protocol for PCI early after operation. Thus, this modified protocol, with continuous use of aspirin and intraoperative administration of loading dose clopidogrel, might be a safe and effective antiplatelet strategy for the one-stop hybrid coronary revascularization.
目的：
一站式复合技术融合了经皮冠状动脉介入治疗(Percutaneous coronary intervention, PCI)和微创冠状动脉旁路移植术(Minimally invasive direct coronary artery bypass, MIDCAB)的优势,在配备有影像学设备的“复合”手术室内对病人实施完全再血管化,并进行实时影像学评价。本研究旨在总结一站式复合技术血运重建治疗冠状动脉多支病变的初步临床经验,并分析一站式复合技术血运重建的安全性和临床应用价值。
方法：
自2007年6月至2009年12月,连续有104例患者在我院接受一站式复合技术血运重建。冠状动脉病变支数平均2.4支／例。首先经胸骨下端小切口在不停跳状态下行LIMA至LAD旁路移植术,即刻冠状动脉造影证实LIMA-LAD通畅后同期对其它冠状动脉病变靶血管行PCI治疗。对围术期抗凝抗血小板方案进行改良如下：围术期持续应用阿司匹林；MIDCAB术后即刻冠状动脉造影证实血运重建满意后给予负荷剂量波立维300mg,术后予维持剂量75mg／天应用12个月。
结果：
共有103例(99.0%)患者成功进行一站式复合技术血运重建,1例(1.0%)患者在对第一钝缘支行PCI治疗时,因钝缘支夹层形成且血流动力学不稳定遂在一站式复合手术室内转为体外循环下CABG.术中冠状动脉造影示4例(3.8%)患者LIMA-LAD吻合不满意,立即再次开胸手术矫正。PCI治疗冠状动脉靶病变188处,平均1.8±0.9支／人；其中12处(6.4%)靶病变仅行PTCA,其余病变均置入支架,共置入191枚DES,3枚BMS。PCI即刻造影成功率为98.4%。术后因呼吸衰竭死亡1例(1.0%),急性肺栓塞1例(1.0%),胸腔积液5例(4.9%),出现新发房颤12例(11.5%)。术后30天内无心肌梗死、因出血而再手术、急性肾功能衰竭、脑血管意外或再血管化等发生。术后平均随访15.0±8.5月,随访期间无死亡、心肌梗死或脑血管意外等发生。术后1年30例(29.4%)患者行冠状动脉造影复查,3例(2.9%)行冠状动脉多层螺旋CT检查,所有LIMA桥血管均证实通畅,未发现支架内狭窄或支架内血栓形成。1例(1.0%)患者在术后1年的冠状动脉造影随访时因回旋支近端新发病变而再次接受PCI再血管化。1例(1.0%)患者心绞痛复发,现药物治疗。
结论：
一站式复合技术再血管化治疗冠状动脉多支病变安全可行。
中文摘要(第二部分)：一站式复合技术与非体外循环冠状动脉旁路移植术治疗冠状动脉多支病变的对比研究
目的：
非体外循环冠状动脉旁路移植术(Off-pump coronary artery bypass, OPCAB)是目前最为常用也是较为成熟的外科血运重建微创术式。本研究旨在比较一站式复合技术与OPCAB治疗冠状动脉多支病变患者的近期临床结果,并评价一站式复合技术治疗冠状动脉多支病变高危患者的临床应用价值。
方法：
自2007年6月至2008年12月,共有52例患者在我院接受一站式复合技术冠状动脉血运重建。同期360例冠状动脉多支病变患者行单纯OPCAB,应用倾向性评分匹配(Propensity score matching)的统计方法抽取52例OPCAB患者与一站式复合技术组患者进行1：1配对。研究终点是两组患者院内临床结果和随访期间的免于主要心脏或脑血管不良事件(Major adverse cardiac or cerebrovascular events, MACCE)发生的生存率。
结果：
两组之间患者基线特征无明显差异。两组院内均无MACCE发生,主要并发症发生率之间无显著差异。一站式复合技术组的ICU滞留时间为(33.3±28.4)小时,呼吸机辅助时间为(11.5±6.9)小时,术后平均住院(8.1±1.7)天,均相应的少于OPCAB组(分别为(49.3±39.0)小时,P=0.03；(18.2±18.2)小时,P=0.0003；(9.1±3.1)天,P=0.047)。一站式复合技术组术后失血量为(860±460)mL,显著少于OPCAB组((1108±59)mL,P=0.02),需要输血的比例(34.6%)显著低于OPCAB组(55.8%,P=0.03)。但一站式复合技术再血管化耗时较长,费用高于OPCAB组。平均随访15.4±5.2个月,一站式复合技术组和OPCAB组之间实际生存率分别为100%和94.2%(Log-rank P=0.11),两组免于MACCE发生的生存率分别为96.2%和90.4%(Log-rank P=0.84),两组之间差异均无统计学意义。
结论：
与OPCAB相比较,一站式复合技术再血管化可减少术后出血量和血液制品的使用,促进术后尽快恢复。近期随访结果显示一站式复合技术可以达到与传统OPCAB相近的临床结果。
中文摘要(第三部分)：一站式复合技术与经皮冠状动脉介入治疗冠状动脉多支病变的对比研究
目的：
PCI是冠状动脉再血管化最为常用的手段。本研究旨在比较一站式复合技术与常规PCI治疗冠状动脉多支病变的近期临床结果,并进一步评价一站式复合技术的临床应用价值。
方法：
自2007年6月至2008年12月,共有52例患者在我院接受一站式复合技术冠状动脉血运重建。同期399例冠状动脉多支病变患者行PCI治疗,应用倾向性评分匹配(Propensity score matching)的统计方法抽取52例OPCAB患者与一站式复合技术组患者进行1：1配对。研究终点是两组患者院内临床结果和随访期间的免于MACCE发生的生存率。
结果：
匹配后两组患者的大部分术前基线资料无显著的统计学差异。两组患者院内均无死亡、围术期心肌梗死、脑卒中、支架内血栓或再次再血管化等发生。一站式复合技术组中有6例(11.5%)为无保护左主干病变。一站式复合技术组前降支系统使用的支架数量(复合技术组0.1±0.3枚／人,PCI组1.1±0.4枚／人,P<0.01)、平均置入的支架数(复合技术组1.7±0.9枚／人,PCI组2.6±0.7枚／人,P<0.001)以及置入支架的长度(复合技术组34.0±20.1mm,PCI组42.2±19.9mm,P=0.04)均显著低于PCI组。一站式复合技术组患者的完全再血管化程度(定义为直径在2.25mm以上且狭窄≥70%的靶血管均得到血运重建)为96.2%,显著高于PCI组(67.3%,P=0.0001)。两组支架置入成功率和院内总费用无显著差异。术后平均随访11.2±4.0个月,两组均无死亡、心梗或脑卒中等不良事件发生,一站式复合技术组1例(1.9%)患者因新发病变而再次血管化,1例(1.9%)患者因首次未完全再血管化而再次行PCI。PCI组有6例(11.5%)患者再次住院行PCI治疗。一站式复合技术组免于MACCE的生存率为96.2%,显著高于PCI组(88.0%,Log-rank P=0.001),差异有统计学意义。
结论：
一站式复合技术再血管化可以安全有效地用于冠状动脉多支病变和无保护左主干病变的治疗。与传统PCI比较,一站式复合技术再血管化可以减少支架的使用数量,提高完全再血管化程度,降低术后近期的MACCE发生率。
中文摘要(第四部分)：应用血小板聚集率评价一站式复合技术血运重建改良抗血小板方案的有效性研究
目的：
一站式复合技术融合了PCI和MIDCAB的优势,可以在配备有影像学设备和心脏外科设备的“复合”手术室内对病人完全再血管化,并进行实时影像学评价。一站式复合技术的出现,为一些具备传统手术高危因素的多支病变患者提供了一种更个性化的治疗选择,但是PCI／支架置入术后必需的抗凝抗血小板治疗与外科术后出血之间的矛盾仍然是该技术临床应用面临的难题。本研究以传统PCI的常规抗凝抗血小板治疗措施为对照,通过评价本研究所采用的抗凝抗血小板策略下围术期血小板活性的变化,评价该抗凝抗血小板治疗措施的有效性。
方法：
自2008年9月至2009年2月,连续有23例冠状动脉多支病变患者(复合技术组)接受一站式复合技术血运重建,选择同期接受传统PCI／支架置入治疗的20例多支病变患者为对照(PCI组)。PCI组患者围术期常规服用阿司匹林300mg／天,术前给予波立维负荷剂量(300mg),此后予75mg／天维持1年。该改良的抗血小板治疗方案为围术期持续应用阿司匹林；MIDCAB术后即刻冠状动脉造影证实血运重建满意后给予负荷剂量波立维300mg,术后予维持剂量75mg／天应用12个月。分别在术前、术后2小时、术后24小时和72小时取血标本,采用光学法血小板聚集实验(Platelet aggregation test, PAgT)检测血小板活性变化。分别通过花生四烯酸(Arachidonic acid, AA)(终浓度为0.5mmol／L)诱导的PAgT和二磷酸腺苷(Adenosine diphosphate, ADP)(终浓度为10μmol／L)诱导的PAgT反映阿司匹林和波立维的血小板抑制效果。
结果：
复合技术组术后24小时血小板数量(160×103／μL)显著低于PCI组(207×103／μL,P=0.0018)。PCI组AA和ADP诱导的血小板聚集率在支架置入前后无明显变化。复合技术组术后24小时AA诱导的血小板聚集率为5.4%,显著高于术前基线值(4.4%,P=0.0079),也显著高于同时期PCI组AA诱导的血小板聚集率(3.5%,P=0.0023)。复合技术组术前ADP诱导的血小板聚集率为67.3%,显著高于同时期的PCI组(53.0%,P=0.011),此后逐渐降低,并于术后2小时和24小时达到与PCI组相似的血小板抑制程度。围术期无支架内血栓形成、因出血再次手术或大量出血等不良事件发生,两组30天内均无死亡、心肌梗死或再血管化等发生。
结论：
本研究的改良抗凝抗血小板方案在围术期持续应用阿司匹林,并在术中PCI之前应用负荷剂量波立维。血小板聚集率变化显示,该方案在术后早期即可达到与常规PCI抗血小板治疗方案相似血小板抑制效果。因此,该改良的抗凝抗血小板方案可安全有效的应用于一站式复合技术血运重建。
ABSTRACT (PART ONE): "One-Stop" Hybrid Coronary Revascularization for Multivessel Coronary Artery Disease with a Modified Antiplatelet Protocol:early and mid-term clinical outcomes
Objective:
"One-stop" hybrid coronary artery revascularization combines minimally invasive direct coronary artery bypass grafting (MIDCAB) and percutaneous coronary intervention (PCI) simultaneously in a single, enhanced operating suite. This study sought to investigate the early and mid-term clinical outcomes of this one-stop hybrid approach with a modified antiplatelet protocol.
Materials and Methods:
From June 2007 to December 2009,104 consecutive patients were planned to undergo one-stop hybrid coronary revascularization. MIDCAB was first performed to anastomosis the left internal mammary artery (LIMA) to the left anterior descending coronary artery (LAD) through lower partial ministernotomy. LIMA-LAD graft patency was then confirmed by coronary angiography. Catheter-based interventions on non-LAD lesions were then completed in the same setting. The modified antiplatelet regimen included perioperative aspirin; clopidogrel was routinely discontinued 7 days or more before operation, and then administered intraoperatively with a 300-mg loading dose, followed by a maintenance dose of 75 mg/day for 12 months.
Results:
One-stop hybrid procedure was successfully carried out in 103 (99.0%) patients. Conversion to conventional on-pump coronary artery bypass grafting (CABG) was required in 1 (1.0%) patient. Four major defects (3.8%) were found in the LIMA grafts and were immediately repaired. A total of 188 lesions were treated by PCI, mean number of lesions treated was 1.8±0.9 per patient. Angiographic success of PCI, based on visual analysis, was obtained in 185 of 188 lesions (98.4%). Balloon angiography alone was used in 12 lesions.191 drug-eluting stents (DES) and 3 bare-mental stents (BMS) were implanted. Angiographic success of stents was 100%. There was 1 (1.0%) deaths within 30 days after operation. One patient (1.0%) developed pulmonary thromboembolism, pleural effusion in 5 (4.9%) patients, and transient atrial fibrillation in 12 (11.5%) patients. All the 102 patients survived the follow-up period of 15.0±8.5 months. No deaths, myocardial infarctions, strokes, recurrent angina, severe bleeding, or stent thrombosis occurred. Thirty patients (29.4%) underwent follow-up coronary angiography and 3 patients (2.9%) underwent 64-slice computed tomography. All LITA grafts were confirmed patent. Only one patient (1.0%) underwent repeat revascularization at the 1-year follow-up angiogram.
Conclusions:
One-stop hybrid coronary revascularization provides a feasible and safe alternative for selected patients with multivessel disease, especially for those at high risk for conventional strategies.
ABSTRACT (PART TWO): Comparison of one-stop hybrid coronary revascularization and off-pump coronary artery bypass in the treatment of multivessel coronary artery disease: a propensity score matching analysis
Objectives:
OPCAB has been widely used as an alternative for the conventional on-pump coronary artery bypass. This study sought to compare the early and short-term clinical outcomes of one-stop hybrid coronary revascularization with those in a matched subset of patients undergoing OPCAB.
Materials and Methods:
From June 2007 to December 2008,52 consecutive patients underwent planned one-stop hybrid revascularization in our institution. By using propensity score matching method, a matched group of 52 patients were selected from a cohort of 360 patients who underwent conventional OPCAB via median sternotomy in our institution during the same period. We compared the in-hospital clinical outcomes and freedom from major adverse cardiac or cerebrovascular events (MACCEs) at follow-up period.
Results:
The baseline characteristics were similar between the two groups. Patients in the hybrid group required shorter intubation times ((11.5±6.9) hours versus 18.2±18.2, P=0.03), shorter lengths of stay in ICU ((33.3±28.4) hours versus (49.3±39.0) hours, P=0.003), less stay in hospital after operation ((8.1±1.7) days versus (9.1±3.1) days, P=0.047). Moreover, the one-stop hybrid group also showed significant reduction in total blood loss ((860±460) mL versus (1108±596) mL, P=0.02) and need of blood transfusion (34.6%versus 55.8%, P=0.03) than the OPCAB group. The in-hospital postoperative major complications were of no significant difference between the two groups. During a mean follow-up of 15.4±5.2 months, the hybrid group showed comparable with the OPCAB group in actual survival (100%versus 94.2%, Log-rank P=0.11) and MACCE-freesurvival (96.2%versus 90.4%, Log-rank P=0.84).
Conclusions:
The one-stop hybrid coronary revascularization shortens patient postoperative recovery, and shows superior in-hospital outcomes and noninferior short-term outcomes compared with OPCAB.
ABSTRACT (PART THREE): Comparison of one-stop hybrid coronary revascularization and percutaneous coronary intervention for the treatment of multivessel coronary artery disease: a propensity score matching analysis
Objectives:
PCI is the most commonly used intervention for coronary artery disease. This study compared one-stop hybrid approach and PCI for treating patients with multivessel or left main coronary artery disease (or both).
Materials and Methods:
From June 2007 to December 2008,52 consecutive patients underwent planned one-stop hybrid revascularization in our institution. By using propensity score matching method, a matched group of 52 patients were selected from a cohort of 399 patients who underwent conventional PCI in our institution during the same period. We compared the in-hospital clinical outcomes and freedom from MACCE at follow-up period.
Results:
Most baseline characteristics were similar between the two groups. No MACCE occurred during the in-hospital period. There were 6 patients (11.5%) with both multivessel and left main coronary artery disease in the one-stop hybrid group. Patients in the hybrid group required less stents implantation in left anterior descending (LAD) artery (0.1±0.3 versus 1.1±0.4, P<0.01) and less stents used per patient (1.7±0.9 versus 2.6±0.7, P<0.001), but achieved more complete revascularization (defined as residual restenosis less than 70%in vessels diameter more than 2.25mm) (96.2%versus 67.3%, P=0.0001). Average total stent length was 34.0±20.1 mm in the one-stop hybrid group versus 42.2±19.9 mm in PCI group (P =0.04). There were no significant differences in success rate of stent implantation and total in-hospital costs between this two groups. During a mean follow-up of (11.2±4.0) months, the hybrid group showed higher MACCE-free survival (96.2%versus 88.0%, Log-rank P=0.001) than the PCI group.
Conclusions:
One-stop hybrid revascularization is a safe and effective alternative for patients with multivessel and/or left main coronary artery disease. Compared with PCI, one-stop hybrid strategy could reduce the number of stent implantation, achieve more complete revascularization and result in greater clinical benefits at short-term follow-up.
ABSTRACT (PART FOUR): Evaluation of antiplatelet effects of a modified protocol by platelet aggregation in patients undergoing "one-stop" hybrid coronary revascularization
Objectives:
"One-stop" hybrid coronary revascularization has emerged to be a reliable and attractive alternative for selected patients with multivessel coronary artery disease. However, the optimal antiplatelet regimen of the one-stop hybrid procedure still remains controversial. We modified the antiplatelet protocol in order to reduce the risk of perioperative bleeding and maximally inhibit platelet activity. This study sought to investigate whether the inhibition of platelet activity by this modified antiplatelet protocol is comparable with the conventional protocol widely used and recommended in percutaneous coronary interventions (PCI).
Materials and Methods:
From September 2008 to February 2009,23 patients undergoing one-stop hybrid procedure and 20 patients undergoing conventional PCI with stenting were enrolled in this prospective study. The modified antiplatelet protocol included perioperative use of aspirin; clopidogrel was administered immediately before PCI with a 300-mg loading dose, followed by a maintenance dose of 75 mg/day for 12 months. Blood samples were obtained before the operation and 2 hours, day 1 and day 3 after operation. Platelet aggregation was induced with:1) arachidonic acid (AA) (final concentration 0.5 mmol/L) to assess the efficacy of aspirin; 2) adenosine diphosphate (ADP) (final concentration 10μmol/L) to assess the specific efficacy of clopidogrel.
Results:
Platelet counts were statistically lower in the hybrid group than in the PCI control group (160×103/μL versus 207×103/μL, P=0.0018) on day 1 after operation. AA-induced platelet aggregation increased significantly in the one-stop hybrid group in comparison with the preoperative baseline values (5.4%versus 4.4%, P=0.0079) and the PCI control group (5.4%versus 3.5%, P=0.0023) on day 1 after operation. ADP-induced platelet aggregation gradually decreased in the hybrid group, and achieved similar platelet inhibition with the PCI group on 2 hours and day 1 after operation. No major adverse clinical events such as death, perioperative myocardial infarction, stent thrombosis, or reoperation for bleeding occurred in both groups within 30 days after procedure.
Conclusions:
This study demonstrates that our modified antiplatelet therapy can sufficiently inhibit platelet activity similarly as the conventional protocol for PCI early after operation. Thus, this modified protocol, with continuous use of aspirin and intraoperative administration of loading dose clopidogrel, might be a safe and effective antiplatelet strategy for the one-stop hybrid coronary revascularization.
引文
1. Hannan EL, Racz M, Holmes DR, Walford G, Sharma S, Katz S, Jones RH, King SB,3rd. Comparison of coronary artery stenting outcomes in the eras before and after the introduction of drug-eluting stents [J]. Circulation. 2008;117(16):2071-2078.
2. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB. Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents [J]. N Engl J Med.2007;356(10):998-1008.
3. Abbott JD, Voss MR, Nakamura M, Cohen HA, Selzer F, Kip KE, Vlachos HA, Wilensky RL, Williams DO. Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice:Findings from the national heart, lung, and blood institute dynamic registry [J]. J Am Coll Cardiol.2007;50(21):2029-2036.
4. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Stahle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease [J]. N Engl J Med.2009;360(10):961-72. Epub 2009 Feb 18.
5. Coronary artery surgery study (cass):A randomized trial of coronary artery bypass surgery. Survival data [J]. Circulation.1983;68(5):939-950.
6. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The bypass angioplasty revascularization investigation (bari) investigators [J]. N Engl J Med.1996;335(4):217-225.
7. Angelini GD, Wilde P, Salerno TA, Bosco G, Calafiore AM. Integrated left small thoracotomy and angioplasty for multivessel coronary artery revascularisation [J]. Lancet.1996;347(9003):757-758.
8. Hu SS. One-stop hybrid approach for cardiovascular disease:From conception to practice [J]. Ann Thorac Cardiovasc Surg.2008;14(6):345-346.
9. Fonger JD. Integrated myocardial revascularization [J]. Eur J Cardiothorac Surg.1999;16 Suppl 2:S12-17.
10. Kpodonu J, Raney A. The cardiovascular hybrid room a key component for hybrid interventions and image guided surgery in the emerging specialty of cardiovascular hybrid surgery [J]. Interact Cardiovasc Thorac Surg. 2009;9(4):688-692.
11. Field ML, Sammut J, Kuduvalli M, Oo A, Rashid A. Hybrid theatres:Nicety or necessity? [J]. J R Soc Med.2009;102(3):92-97.
12.高培显,熊辉,胡盛寿.杂交(hybrid)技术治疗冠状动脉多支病变：进展和争议[J].中华胸心血管外科杂志.2009；25(4)：274-276
13.胡盛寿.正值“复合”(hybrid)技术的时代[J].中华心血管病杂志.2008；36(1)：1-2.
14.胡盛寿,高润霖,郑哲,徐波.Hybrid技术治疗多支病变冠状动脉粥样硬化性心脏病[J].中国胸心血管外科临床杂志.2000；7(4)：273-274.
15. Gao R, Hu S, Zheng Z, Yang Y, Qiao S, Qin X, Yao M, Liu H, Jilin Chen, Xu B. "Hybrid" Revascularization:Vi deo-thoracoscopy assisted midcab combined with angioplasty [J]. J Invasive Cardiol.2001;13(3):257-259.
16. Kiaii B, McClure RS, Kostuk WJ, Rayman R, Swinamer S, Dobkowski WB, Novick RJ. Concurrent robotic hybrid revascularization using an enhanced operative suite [J]. Chest.2005;128(6):4046-4048.
17. Kon ZN, Brown EN, Tran R, Joshi A, Reicher B, Grant MC, Kallam S, Burris N, Connerney I, Zimrin D, Poston RS. Simultaneous hybrid coronary revascularization reduces postoperative morbidity compared with results from conventional off-pump coronary artery bypass [J]. J Thorac Cardiovasc Surg. 2008;135(2):367-375.
18. Reicher B, Poston RS, Mehra MR, Joshi A, Odonkor P, Kon Z, Reyes PA, Zimrin DA. Simultaneous "Hybrid" Percutaneous coronary intervention and minimally invasive surgical bypass grafting:Feasibility, safety, and clinical outcomes [J]. Am Heart J.2008;155(4):661-667.
19. Zhao DX, Leacche M, Balaguer JM, Boudoulas KD, Damp JA, Greelish JP, Byrne JG, Ahmad RM, Ball SK, Cleator JH, Deegan RJ, Eagle SS, Fong PP, Fredi JL, Hoff SJ, Jennings HS,3rd, McPherson JA, Piana RN, Pretorius M, Robbins MA, Slosky DA, Thompson A. Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/operating room [J]. J Am Coll Cardiol.2009;53(3):232-241.
20. Stahl KD, Boyd WD, Vassiliades TA, Karamanoukian HL. Hybrid robotic coronary artery surgery and angioplasty in multivessel coronary artery disease [J]. Ann Thorac Surg.2002;74(4):S1358-1362.
21. Murphy GJ, Bryan AJ, Angelini GD. Hybrid coronary revascularization in the era of drug-eluting stents [J]. Ann Thorac Surg.2004;78(5):1861-1867.
22. Katz MR, Van Praet F, de Canniere D, Murphy D, Siwek L, Seshadri-Kreaden U, Friedrich G, Bonatti J. Integrated coronary revascularization:Percutaneous coronary intervention plus robotic totally endoscopic coronary artery bypass [J]. Circulation.2006;114(1 Suppl):I473-476.
23. Riess FC, Schofer J, Kremer P, Riess AG, Bergmann H, Moshar S, Mathey D, Bleese N. Beating heart operations including hybrid revascularization:Initial experiences [J]. Ann Thorac Surg.1998;66(3):1076-1081.
24. Cohen HA, Zenati M, Smith AJ, Lee JS, Chough S, Jafar Z, Counihan P, Izzo M, Burchenal JE, Feldman AM, Griffith B. Feasibility of combined percutaneous transluminal angioplasty and minimally invasive direct coronary artery bypass in patients with multivessel coronary artery disease [J]. Circulation.1998;98(11):1048-1050.
25. Riess FC, Bader R, Kremer P, Kuhn C, Kormann J, Mathey D, Moshar S, Tuebler T, Bleese N, Schofer J. Coronary hybrid revascularization from January 1997 to january 2001:A clinical follow-up [J]. Ann Thorac Surg. 2002;73(6):1849-1855.
26. Wittwer T, Cremer J, Boonstra P, Grandjean J, Mariani M, Mugge A, Drexler H, den Heijer P, Leitner ER, Hepp A, Wehr M, Haverich A. Myocardial "Hybrid" Revascularisation with minimally invasive direct coronary artery bypass grafting combined with coronary angioplasty:Preliminary results of a multicentre study [J]. Heart.2000;83(1):58-63.
27. 胡盛寿,高润霖,高培显,李立环,熊辉,徐波,杨跃进,袁晋青,郑哲.一站式复合血管重建技术治疗无保护左主干病变[J].中华心血管病杂志.2010；38(1)：23-26.
28. Niinami H, Ogasawara H, Suda Y, Takeuchi Y. Single-vessel revascularization with minimally invasive direct coronary artery bypass:Minithoracotomy or ministernotomy? [J]. Chest.2005;127(1):47-52.
29. Niinami H, Takeuchi Y, Ichikawa S, Suda Y. Partial median sternotomy as a minimal access for off-pump coronary artery bypass grafting:Feasibility of the lower-end sternal splitting approach [J]. Ann Thorac Surg. 2001;72(3):S1041-1045.
30. 马维国,孙寒松,胡盛寿,许建屏,吕锋,朱晓东.胸骨下段正中小切口直视冠状动脉旁路移植术 [J].中国胸心血管外科临床杂志2005；12(4)：240-243.
31. Oehlinger A, Bonaros N, Schachner T, Ruetzler E, Friedrich G, Laufer G, Bonatti J. Robotic endoscopic left internal mammary artery harvesting:What have we learned after 100 cases? [J]. Ann Thorac Surg.2007;83(3):1030-1034.
32. Kiaii B, McClure RS, Stitt L, Rayman R, Dobkowski WB, Jablonsky G, Novick RJ, Boyd WD. Prospective angiographic comparison of direct, endoscopic, and telesurgical approaches to harvesting the internal thoracic artery [J]. Ann Thorac Surg.2006;82(2):624-628.
33. Kappert U, Schneider J, Cichon R, Gulielmos V, Tugtekin SM, Nicolai J, Matschke K, Schueler S. Development of robotic enhanced endoscopic surgery for the treatment of coronary artery disease [J]. Circulation. 2001;104(12 Suppl 1):I102-107.
1. Moller CH, Penninga L, Wetterslev J, Steinbruchel DA, Gluud C. Clinical outcomes in randomized trials of off-vs. On-pump coronary artery bypass surgery:Systematic review with meta-analyses and trial sequential analyses [J]. Eur Heart J.2008;29(21):2601-2616.
2. Hannan EL, Wu C, Smith CR, Higgins RS, Carlson RE, Culliford AT, Gold JP, Jones RH. Off-pump versus on-pump coronary artery bypass graft surgery: Differences in short-term outcomes and in long-term mortality and need for subsequent revascularization [J]. Circulation.2007; 116(10):1145-1152.
3. Li Y, Zheng Z, Hu S. Early and long-term outcomes in the elderly: Comparison between off-pump and on-pump techniques in 1191 patients undergoing coronary artery bypass grafting [J]. J Thorac Cardiovasc Surg. 2008;136(3):657-664.
4. Hu S, Zheng Z, Yuan X, Wang W, Song Y, Sun H, Xu J. Increasing long-term major vascular events and resource consumption in patients receiving off-pump coronary artery bypass:A single-center prospective observational study [J]. Circulation.2010; 121(16):1800-1808.
5. Hu SS. One-stop hybrid approach for cardiovascular disease:From conception to practice [J]. Ann Thorac Cardiovasc Surg.2008;14(6):345-346
6.胡盛寿.正值“复合”(hybrid)技术的时代[J].中华心血管病杂志.2008；36(1)：1-2.
7. Reicher B, Poston RS, Mehra MR, Joshi A, Odonkor P, Kon Z, Reyes PA, Zimrin DA. Simultaneous "Hybrid" Percutaneous coronary intervention and minimally invasive surgical bypass grafting:Feasibility, safety, and clinical outcomes [J]. Am Heart J.2008; 155(4):661-667.
8. Kon ZN, Brown EN, Tran R, Joshi A, Reicher B, Grant MC, Kallam S, Burris N, Connerney I, Zimrin D, Poston RS. Simultaneous hybrid coronary revascularization reduces postoperative morbidity compared with results from conventional off-pump coronary artery bypass [J]. J Thorac Cardiovasc Surg. 2008;135(2):367-375.
9. Kiaii B, McClure RS, Stewart P, Rayman R, Swinamer SA, Suematsu Y, Fox S, Higgins J, Albion C, Kostuk WJ, Almond D, Sridhar K, Teefy P, Jablonsky G, Diamantouros P, Dobkowski WB, Jones P, Bainbridge D, Iglesias I, Murkin J,
Cheng D, Novick RJ. Simultaneous integrated coronary artery revascularization with long-term angiographic follow-up [J]. J Thorac Cardiovasc Surg.2008;136(3):702-708.
10. Bonatti J, Schachner T, Bonaros N, Jonetzko P, Ohlinger A, Ruetzler E, Kolbitsch C, Feuchtner G, Laufer G, Pachinger O, Friedrich G. Simultaneous hybrid coronary revascularization using totally endoscopic left internal mammary artery bypass grafting and placement of rapamycin eluting stents in the same interventional session. The combination pilot study [J]. Cardiology. 2008;110(2):92-95.
11. Zhao DX, Leacche M, Balaguer JM, Boudoulas KD, Damp JA, Greelish JP, Byrne JG, Ahmad RM, Ball SK, Cleator JH, Deegan RJ, Eagle SS, Fong PP, Fredi JL, Hoff SJ, Jennings HS,3rd, McPherson JA, Piana RN, Pretorius M, Robbins MA, Slosky DA, Thompson A. Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/operating room [J]. J Am Coll Cardiol.2009;53(3):232-241.
12. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects [J]. Biometrika.1983;70(1):41.
13. 赵守军,张勇,汪萱怡,高燕宁.均衡组间差异的有效方法：倾向评分[J].中华流行病学杂志.2003；24(6)：516-519.
14. Blackstone EH. Comparing apples and oranges [J]. J Thorac Cardiovasc Surg. 2002;123(1):8-15.
15. Rubin DB. The design versus the analysis of observational studies for causal effects:Parallels with the design of randomized trials [J]. Stat Med. 2007;26(1):20-36.
16. Rubin DB. Estimating causal effects from large data sets using propensity scores [J]. Ann Intern Med.1997; 127(8 Pt 2):757-763.
17. Synnergren MJ, Ekroth R, Oden A, Rexius H, Wiklund L. Incomplete revascularization reduces survival benefit of coronary artery bypass grafting: Role of off-pump surgery [J]. J Thorac Cardiovasc Surg.2008;136(1):29-36.
18. Lim E, Drain A, Davies W, Edmonds L, Rosengard BR. A systematic review of randomized trials comparing revascularization rate and graft patency of off-pump and conventional coronary surgery [J]. J Thorac Cardiovasc Surg. 2006;132(6):1409-1413.
19. Takagi H, Tanabashi T, Kawai N, Kato T, Umemoto T. Off-pump coronary artery bypass sacrifices graft patency:Meta-analysis of randomized trials [J]. J Thorac Cardiovasc Surg.2007;133(1):e2-3.
20. Parolari A, Camera M, Alamanni F, Naliato M, Polvani GL, Agrifoglio M, Brambilla M, Biancardi C, Mussoni L, Biglioli P, Tremoli E. Systemic inflammation after on-pump and off-pump coronary bypass surgery:A one-month follow-up [J]. Ann Thorac Surg.2007;84(3):823-828.
21. van Dijk D, Spoor M, Hijman R, Nathoe HM, Borst C, Jansen EW, Grobbee DE, de Jaegere PP, Kalkman CJ. Cognitive and cardiac outcomes 5 years after off-pump vs on-pump coronary artery bypass graft surgery [J]. JAMA. 2007;297(7):701-708.
22. Van Dijk D, Jansen EW, Hijman R, Nierich AP, Diephuis JC, Moons KG, Lahpor JR, Borst C, Keizer AM, Nathoe HM, Grobbee DE, De Jaegere PP, Kalkman CJ. Cognitive outcome after off-pump and on-pump coronary artery bypass graft surgery:A randomized trial [J]. JAMA.2002;287(11):1405-1412.
23. Angelini GD, Wilde P, Salerno TA, Bosco G, Calafiore AM. Integrated left small thoracotomy and angioplasty for multivessel coronary artery revascularisation [J]. Lancet.1996;347(9003):757-758.
24. Lev-Ran O, Braunstein R, Sharony R, Kramer A, Paz Y, Mohr R, Uretzky G. No-touch aorta off-pump coronary surgery:The effect on stroke [J]. J Thorac Cardiovasc Surg.2005;129(2):307-313.
25. 马维国,孙寒松,胡盛寿,许建屏,吕锋,朱晓东.胸骨下段正中小切口直视冠状动脉旁路移植术[J].中国胸心血管外科临床杂志.2005；12(4)：240-243.
26. Niinami H, Ogasawara H, Suda Y, Takeuchi Y. Single-vessel revascularization with minimally invasive direct coronary artery bypass:Minithoracotomy or ministernotomy? [J]. Chest.2005;127(1):47-52.
27. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB, Jr., Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT. Efficacy and safety of edifoligide, an e2f transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery:Prevent iv:A randomized controlled trial [J]. JAMA. 2005;294(19):2446-2454.
28. Mack MJ. Intraoperative coronary graft assessment [J]. Curr Opin Cardiol. 2008;23(6):568-572.
29. D'Ancona G, Bartolozzi F, Bogers AJ, Pilato M, Parrinello M, Kappetein AP. Intraoperative graft patency verification in coronary artery surgery:Modern diagnostic tools [J]. J Cardiothorac Vasc Anesth.2009;23(2):232-238.
30. Wittwer T, Cremer J, Boonstra P, Grandjean J, Mariani M, Mugge A, Drexler H, den Heijer P, Leitner ER, Hepp A, Wehr M, Haverich A. Myocardial "Hybrid" Revascularisation with minimally invasive direct coronary artery bypass grafting combined with coronary angioplasty:Preliminary results of a multicentre study [J]. Heart.2000;83(1):58-63.
1. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, Davis K, Killip T, Passamani E, Norris R, et al. Effect of coronary artery bypass graft surgery on survival:Overview of 10-year results from randomised trials by the coronary artery bypass graft surgery trialists collaboration [J]. Lancet. 1994;344(8922):563-570.
2. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Jr., Chavey WE,2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC, Jr., Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B. Acc/aha 2007 guidelines for the management of patients with unstable angina/non-st-elevation myocardial infarction:A report of the american college of cardiology/american heart association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-st-elevation myocardial infarction) developed in collaboration with the american college of emergency physicians, the society for cardiovascular angiography and interventions, and the society of thoracic surgeons endorsed by the american association of cardiovascular and pulmonary rehabilitation and the society for academic emergency medicine [J]. J Am Coll Cardiol.2007;50(7):el-e157.
3.胡盛寿,张浩.微创心脏外科学的概念和发展[J].中国微创外科杂志.2006；6(6)：404-406.
4. Angelini GD, Wilde P, Salerno TA, Bosco G, Calafiore AM. Integrated left small thoracotomy and angioplasty for multivessel coronary artery revascularisation [J]. Lancet.1996;347(9003):757-758.
5. Fonger JD. Integrated myocardial revascularization [J]. Eur J Cardiothorac Surg.1999;16 Suppl 2:S12-17.
6.胡盛寿,高润霖,郑哲,徐波.Hybrid技术治疗多支病变冠状动脉粥样硬化性心脏病[J].中国胸心血管外科临床杂志.2000；7(4)：273-274.
7.赵强,夏利民,陈安清,王哲,徐德民.杂交技术在冠状动脉外科中的应用[J].中国微创外科杂志.2006；6(6)：421-423.
8.王东进,邵峻,梁雨露,武忠,潘俊.胸腔镜辅助下冠状动脉旁路移植术与介入联合治疗冠心病多支病变七例[J]．中华心血管病杂志. 2006;34(3):247-248.
9. Kon ZN, Brown EN, Tran R, Joshi A, Reicher B, Grant MC, Kallam S, Burris N, Connerney I, Zimrin D, Poston RS. Simultaneous hybrid coronary revascularization reduces postoperative morbidity compared with results from conventional off-pump coronary artery bypass [J]. J Thorac Cardiovasc Surg. 2008;135(2):367-375.
10. Reicher B, Poston RS, Mehra MR, Joshi A, Odonkor P, Kon Z, Reyes PA, Zimrin DA. Simultaneous "Hybrid" Percutaneous coronary intervention and minimally invasive surgical bypass grafting:Feasibility, safety, and clinical outcomes [J]. Am Heart J.2008;155(4):661-667.
11. 胡盛寿.正值“复合”(hybrid)技术的时代[J].中华心血管病杂志.2008；36(1)：1-2.
12. 胡盛寿,张浩.微创心血管外科的一个全新概念--一站式杂交手术[J].中国微创外科杂志.2005；5(12)：975.
13. Reicher B, Poston RS, Mehra MR, Joshi A, Odonkor P, Kon Z, Reyes PA, Zimrin DA. Simultaneous "Hybrid" Percutaneous coronary intervention and minimally invasive surgical bypass grafting:Feasibility, safety, and clinical outcomes [J]. Am Heart J.2008;155(4):661-667.
14. Kiaii B, McClure RS, Stewart P, Rayman R, Swinamer SA, Suematsu Y, Fox S, Higgins J, Albion C, Kostuk WJ, Almond D, Sridhar K, Teefy P, Jablonsky G, Diamantouros P, Dobkowski WB, Jones P, Bainbridge D, Iglesias I, Murkin J, Cheng D, Novick RJ. Simultaneous integrated coronary artery revascularization with long-term angiographic follow-up [J]. J Thorac Cardiovasc Surg.2008;136(3):702-708.
15. Bonatti J, Schachner T, Bonaros N, Jonetzko P, Ohlinger A, Ruetzler E, Kolbitsch C, Feuchtner G, Laufer G, Pachinger O, Friedrich G. Simultaneous hybrid coronary revascularization using totally endoscopic left internal mammary artery bypass grafting and placement of rapamycin eluting stents in the same interventional session. The combination pilot study [J]. Cardiology. 2008;110(2):92-95.
16. Li Y, Zheng Z, Xu B, Zhang S, Li W, Gao R, Hu S. Comparison of drug-eluting stents and coronary artery bypass surgery for the treatment of multivessel coronary disease:Three-year follow-up results from a single institution [J]. Circulation.2009;119(15):2040-2050.
17. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents [J]. N Engl J Med.2007;356(10):1020-1029.
18. Pinto Slottow TL, Waksman R. Overview of the 2006 food and drug administration circulatory system devices panel meeting on drug-eluting stent thrombosis [J]. Catheter Cardiovasc Interv.2007;69(7):1064-1074.
19. Goldman S, Zadina K, Moritz T, Ovitt T, Sethi G, Copeland JG, Thottapurathu L, Krasnicka B, Ellis N, Anderson RJ, Henderson W. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery:Results from a department of veterans affairs cooperative study [J]. J Am Coll Cardiol.2004;44(11):2149-2156.
20. Aziz O, Rao C, Panesar SS, Jones C, Morris S, Darzi A, Athanasiou T. Meta-analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery [J]. BMJ.2007;334(7594):617.
21. Zimrin D, Reyes PA, Reicher B, Poston RS. A hybrid alternative for high risk left main disease [J]. Catheter Cardiovasc Interv.2007;69(1):123-127.
22. Valgimigli M, Malagutti P, Rodriguez-Granillo GA, Garcia-Garcia HM, Polad J, Tsuchida K, Regar E, Van der Giessen WJ, de Jaegere P, De Feyter P, Serruys PW. Distal left main coronary disease is a major predictor of outcome in patients undergoing percutaneous intervention in the drug-eluting stent era: An integrated clinical and angiographic analysis based on the rapamycin-eluting stent evaluated at rotterdam cardiology hospital (research) and taxus-stent evaluated at rotterdam cardiology hospital (t-search) registries [J]. J Am Coll Cardiol.2006;47(8):1530-1537.
23. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Jr., Chavey WE,2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC, Jr., Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B. Acc/aha 2007 guidelines for the management of patients with unstable angina/non st-elevation myocardial infarction:A report of the american college of cardiology/american heart association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non st-elevation myocardial infarction):Developed in collaboration with the american college of emergency physicians, the society for cardiovascular angiography and interventions, and the society of thoracic surgeons:Endorsed by the american association of cardiovascular and pulmonary rehabilitation and the society for academic emergency medicine [J]. Circulation.2007;116(7):e148-304.
24. 胡盛寿,高润霖,高培显,李立环,熊辉,徐波,杨跃进,袁晋青,郑哲.-站式复合血管重建技术治疗无保护左主干病变[J].中华心血管病杂志.2010；38(1)：23-26.
25. Lopez JJ, Ho KK, Stoler RC, Caputo RP, Carrozza JP, Kuntz RE, Baim DS, Cohen DJ. Percutaneous treatment of protected and unprotected left main coronary stenoses with new devices:Immediate angiographic results and intermediate-term follow-up [J]. J Am Coll Cardiol.1997;29(2):345-352.
26. Miketic S, Carlsson J, Neuhaus KL, Bonzel T, Grube E, Tebbe U. Percutaneous transluminal coronary angioplasty of left main stenosis-results of the german ptca registry [J]. Z Kardiol.2000;89(6):508-512.
27. Kelley MP, Klugherz BD, Hashemi SM, Meneveau NF, Johnston JM, Matthai WH, Jr., Banka VS, Herrmann HC, Hirshfeld JW, Jr., Kimmel SE, Kolansky DM, Horwitz PA, Schiele F, Bassand JP, Wilensky RL. One-year clinical outcomes of protected and unprotected left main coronary artery stenting [J]. Eur Heart J.2003;24(17):1554-1559.
1. Angelini GD, Wilde P, Salerno TA, Bosco G, Calafiore AM. Integrated left small thoracotomy and angioplasty for multivessel coronary artery revascularisation [J]. Lancet.1996;347(9003):757-758.
2. Fonger JD. Integrated myocardial revascularization [J]. Eur J Cardiothorac Surg.1999;16 Suppl 2:S12-17.
3. Friedrich GJ, Bonatti J. Hybrid coronary artery revascularization-review and update 2007 [J]. Heart Surg Forum.2007;10(4):E292-296.
4. Kiaii B, McClure RS, Kostuk WJ, Rayman R, Swinamer S, Dobkowski WB, Novick RJ. Concurrent robotic hybrid revascularization using an enhanced operative suite [J]. Chest.2005;128(6):4046-4048.
5. 胡盛寿.正值“复合”(hybrid)技术的时代[J].中华心血管病杂志.2008；36(1)：1-2.
6. Reicher B, Poston RS, Mehra MR, Joshi A, Odonkor P, Kon Z, Reyes PA, Zimrin DA. Simultaneous "Hybrid" Percutaneous coronary intervention and minimally invasive surgical bypass grafting:Feasibility, safety, and clinical outcomes [J]. Am Heart J.2008;155(4):661-667.
7. Kon ZN, Brown EN, Tran R, Joshi A, Reicher B, Grant MC, Kallam S, Burris N, Connerney I, Zimrin D, Poston RS. Simultaneous hybrid coronary revascularization reduces postoperative morbidity compared with results from conventional off-pump coronary artery bypass [J]. J Thorac Cardiovasc Surg. 2008;135(2):367-375.
8. Kiaii B, McClure RS, Stewart P, Rayman R, Swinamer SA, Suematsu Y, Fox S. Higgins J, Albion C, Kostuk WJ, Almond D, Sridhar K, Teefy P, Jablonsky G, Diamantouros P, Dobkowski WB, Jones P, Bainbridge D, Iglesias I, Murkin J, Cheng D, Novick RJ. Simultaneous integrated coronary artery revascularization with long-term angiographic follow-up [J]. J Thorac Cardiovasc Surg.2008;136(3):702-708.
9. Hu SS. One-stop hybrid approach for cardiovascular disease:From conception to practice [J]. Ann Thorac Cardiovasc Surg.2008;14(6):345-346.
10. Bonatti J, Schachner T, Bonaros N, Jonetzko P, Ohlinger A, Ruetzler E, Kolbitsch C, Feuchtner G, Laufer G, Pachinger O, Friedrich G. Simultaneous hybrid coronary revascularization using totally endoscopic left internal mammary artery bypass grafting and placement of rapamycin eluting stents in the same interventional session. The combination pilot study [J]. Cardiology. 2008;110(2):92-95.
11. 高培显,熊辉,胡盛寿.杂交(hybrid)技术治疗冠状动脉多支病变：进展和争议[J].中华胸心血管外科杂志.2009；25(4)：274-276.
12. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study [J]. Lancet. 2007;369(9562):667-678
13. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, Gick M, Caputo A, Buttner HJ, Neumann FJ. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement [J]. J Am Coll Cardiol. 2006;48(9):1742-1750.
14. Marcucci R, Paniccia R, Antonucci E, Poli S, Gori AM, Valente S, Giglioli C, Lazzeri C, Prisco D, Abbate R, Gensini GF. Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy [J]. Thromb Haemost.2007;98(4):844-851.
15. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, Moschi G, Gori AM, Abbate R, Antoniucci D. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis [J]. J Am Coll Cardiol.2007;49(24):2312-2317.
16. Gurbel PA. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events:Emergence of a new cardiovascular risk factor [J]. Rev Cardiovasc Med.2006;7 Suppl 4:S20-28.
17. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US. Platelet reactivity in patients and recurrent events post-stenting: Results of the prepare post-stenting study [J]. J Am Coll Cardiol. 2005;46(10):1820-1826.
18. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents [J]. N Engl J Med.2007;356(10):1020-1029.
19. Pinto Slottow TL, Waksman R. Overview of the 2006 food and drug administration circulatory system devices panel meeting on drug-eluting stent thrombosis [J]. Catheter Cardiovasc Interv.2007;69(7):1064-1074.
20. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents [J]. JAMA.2005;293(17):2126-2130.
21. Shim JH, Jo WM, Chung WJ, Chung JH. Unexpected stent thrombus after minimally invasive direct coronary artery bypass in hybrid re-vascularisation [J]. Eur J Cardiothorac Surg.2009.
22. Brilakis ES, Banerjee S, Berger PB. Perioperative management of patients with coronary stents [J]. J Am Coll Cardiol.2007;49(22):2145-2150.
23. Sautter RD, Myers WO, Ray JF,3rd, Wenzel FJ. Relationship of fibrinolytic system to postoperative thrombotic phenomena [J]. Arch Surg. 1973;107(2):292-296.
24. Bednar F, Osmancik P, Vanek T, Mocikova H, Jares M, Straka Z, Widimsky P. Platelet activity and aspirin efficacy after off-pump compared with on-pump coronary artery bypass surgery:Results from the prospective randomized trial prague 11-coronary artery bypass and reactivity of thrombocytes (cabaret) [J]. J Thorac Cardiovasc Surg.2008;136(4):1054-1060.
25. Hongo RH, Ley J, Dick SE, Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting [J]. J Am Coll Cardiol.2002;40(2):231-237.
26. Chu MW, Wilson SR, Novick RJ, Stitt LW, Quantz MA. Does clopidogrel increase blood loss following coronary artery bypass surgery? [J]. Ann Thorac Surg.2004;78(5):1536-1541.
27. Byrne JG, Leacche M, Unic D, Rawn JD, Simon DI, Rogers CD, Cohn LH. Staged initial percutaneous coronary intervention followed by valve surgery ("Hybrid approach") for patients with complex coronary and valve disease [J]. J Am Coll Cardiol.2005;45(1):14-18.
28. Byrne JG, Leacche M, Vaughan DE, Zhao DX. Hybrid cardiovascular procedures [J]. JACC Cardiovasc Interv.2008;1(5):459-468.
29. Leong JY, Baker RA, Shah PJ, Cherian VK, Knight JL. Clopidogrel and bleeding after coronary artery bypass graft surgery [J]. Ann Thorac Surg. 2005;80(3):928-933.
30. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting:Response variability, drug resistance, and the effect of pretreatment platelet reactivity [J]. Circulation.2003;107(23):2908-2913.
31. Zhao DX, Leacche M, Balaguer JM, Boudoulas KD, Damp JA, Greelish JP, Byrne JG, Ahmad RM, Ball SK, Cleator JH, Deegan RJ, Eagle SS, Fong PP, Fredi JL, Hoff SJ, Jennings HS,3rd, McPherson JA, Piana RN, Pretorius M, Robbins MA, Slosky DA, Thompson A. Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/operating room [J]. J Am Coll Cardiol.2009;53(3):232-241.
32. Maltais S, Perrault LP, Do QB. Effect of clopidogrel on bleeding and transfusions after off-pump coronary artery bypass graft surgery:Impact of discontinuation prior to surgery [J]. Eur J Cardiothorac Surg. 2008;34(1):127-131.
33. Tschoepe D, Schultheiss HP, Kolarov P, Schwippert B, Dannehl K, Nieuwenhuis HK, Kehrel B, Strauer B, Gries FA. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after ptca [J]. Circulation.1993;88(1):37-42.
34. Gawaz M, Neumann FJ, Ott I, May A, Schomig A. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy [J]. Circulation. 1996;94(3):279-285.
35. Michelson AD. Platelet function testing in cardiovascular diseases [J]. Circulation.2004;110(19):e489-493.
36. Kabbani SS, Watkins MW, Ashikaga T, Terrien EF, Holoch PA, Sobel BE, Schneider DJ. Platelet reactivity characterized prospectively:A determinant of outcome 90 days after percutaneous coronary intervention [J]. Circulation. 2001;104(2):181-186.
37. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation [J]. N Engl J Med.2001;345(7):494-502.
38. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting:The clopidogrel aspirin stent international cooperative study (classics) [J]. Circulation.2000;102(6):624-629.
39. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention:The pci-cure study [J]. Lancet.2001;358(9281):527-533.
40. Steinhubl SR, Berger PB, Mann JT,3rd, Fry ET, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention:A randomized controlled trial [J]. JAMA. 2002;288(19):2411-2420.
41. Gianetti J, Parri MS, Sbrana S, Paoli F, Maffei S, Paradossi U, Berti S, Clerico A, Biagini A. Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty:A 6 months prospective study [J]. Thromb Res.2006;118(4):487-493.
42. Gurbel PA, Cummings CC, Bell CR, Alford AB, Meister AF, Serebruany VL. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting:The plavix reduction of new thrombus occurrence (pronto) trial [J]. Am Heart J.2003;145(2):239-247.
43. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, Bonnet JL, Alessi MC. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome [J]. J Thromb Haemost. 2006;4(3):542-549.
44. L'Allier PL, Ducrocq G, Pranno N, Noble S, Ibrahim R, Gregoire JC, Azzari F, Nozza A, Berry C, Doucet S, Labarthe B, Theroux P, Tardif JC. Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens:Results from the prepair randomized study [J]. J Am Coll Cardiol.2008;51(11):1066-1072.
45. Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, Ormiston J, El-Jack S, Armstrong G, Kay P, Scott D, Gunes A, Dahl ML. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel:The princ (plavix response in coronary intervention) trial [J]. JACC Cardiovasc
Interv.2008;1(6):612-619.
46. Cannon CP, Maraganore JM, Loscalzo J, McAllister A, Eddings K, George D, Selwyn AP, Adelman B, Fox I, Braunwald E, et al. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease [J]. Am J Cardiol.1993;71(10):778-782.
47. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM. Bivalirudin for patients with acute coronary syndromes [J]. N Engl J Med.2006;355(21):2203-2216.
48. Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention:A subgroup analysis from the acute catheterization and urgent intervention triage strategy (acuity) trial [J]. Lancet.2007;369(9565):907-919.
49. Feit F, Manoukian SV, Ebrahimi R, Pollack CV, Ohman EM, Attubato MJ, Mehran R, Stone GW. Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes:A report from the acuity (acute catheterization and urgent intervention triage strategy) trial [J]. J Am Coll Cardiol.2008;51(17):1645-1652.
50. White HD, Chew DP, Hoekstra JW, Miller CD, Pollack CV, Jr., Feit F, Lincoff AM, Bertrand M, Pocock S, Ware J, Ohman EM, Mehran R, Stone GW. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-st-segment elevation acute coronary syndromes managed with an invasive strategy:Results from the acuity (acute catheterization and urgent intervention triage strategy) trial [J]. J Am Coll Cardiol.2008;51(18):1734-1741.
51. Dyke CM, Smedira NG, Koster A, Aronson S, McCarthy HL,2nd, Kirshner R, Lincoff AM, Spiess BD. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass:The evolution-on study [J]. J Thorac Cardiovasc Surg.2006;131(3):533-539.
52. Smedira NG, Dyke CM, Koster A, Jurmann M, Bhatia DS, Hu T, McCarthy HL,2nd, Lincoff AM, Spiess BD, Aronson S. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting:The results of the evolution-off study [J]. J Thorac Cardiovasc Surg.2006;131(3):686-692.
53. Palmer GJ, Sankaran IS, Sparkman GM, Koster A, Dyke CM, Ebra G. Routine use of the direct thrombin inhibitor bivalirudin for off-pump coronary artery bypass grafting is safe and effective [J]. Heart Surg Forum. 2008; 11(1):E24-29.
54. Murphy GS, Marymont JH. Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery [J]. J Cardiothorac Vasc Anesth.2007;21(1):113-126.
55. Schuhlen H, Kastrati A, Pache J, Dirschinger J, Schomig A. Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement:Analysis of 5,678 patients with a four-week ticlopidine regimen [J]. J Am Coll Cardiol.2001;37(8):2066-2073.
56. Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, Seth A, Sousa JE, Wijns W, Berge C, Deme M, Stoll HP. Safety of coronary sirolimus-eluting stents in daily clinical practice:One-year follow-up of the e-cypher registry [J]. Circulation.2006;113(11):1434-1441.
57. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent anticoagulation restenosis study investigators [J]. N Engl J Med.1998;339(23):1665-1671.
58. Harrison P, Frelinger AL,3rd, Furman MI, Michelson AD. Measuring antiplatelet drug effects in the laboratory [J]. Thromb Res. 2007;120(3):323-336.
1. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, Davis K, Killip T, Passamani E, Norris R, et al. Effect of coronary artery bypass graft surgery on survival:Overview of 10-year results from randomised trials by the coronary artery bypass graft surgery trialists collaboration [J]. Lancet. 1994;344(8922):563-570.
2. De Maria R, Repossini A, Dabdoob W, Parolini M, Cianci V, Bestetti A, Binetti G, Arena V, Parodi O. Myocardial perfusion imaging evidence of functionally complete revascularization by minimally invasive direct coronary artery bypass in 2-vessel coronary artery disease [J]. J Nucl Cardiol.2007;14(6):860-868.
3. Kim KB, Cho KR, Jeong DS. Midterm angiographic follow-up after off-pump coronary artery bypass:Serial comparison using early,1-year, and 5-year postoperative angiograms [J]. J Thorac Cardiovasc Surg.2008;135(2):300-307.
4. Goldman S, Zadina K, Moritz T, Ovitt T, Sethi G, Copeland JG, Thottapurathu L, Krasnicka B, Ellis N, Anderson RJ, Henderson W. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery:Results from a department of veterans affairs cooperative study [J]. J Am Coll Cardiol.2004;44(11):2149-2156.
5. Loop FD, Lytle BW, Cosgrove DM, Stewart RW, Goormastic M, Williams GW, Golding LA, Gill CC, Taylor PC, Sheldon WC, et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events [J]. N Engl J Med.1986;314(1):1-6.
6. Tatoulis J, Buxton BF, Fuller JA. Patencies of 2127 arterial to coronary conduits over 15 years [J]. Ann Thorac Surg.2004;77(1):93-101.
7. Sabik JF,3rd, Lytle BW, Blackstone EH, Houghtaling PL, Cosgrove DM. Comparison of saphenous vein and internal thoracic artery graft patency by coronary system [J]. Ann Thorac Surg.2005;79(2):544-551; discussion 544-551.
8. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome:Angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years [J]. J Am Coll Cardiol.1996;28(3):616-626.
9. Hannan EL, Wu C, Walford G, Culliford AT, Gold JP, Smith CR, Higgins RS, Carlson RE, Jones RH. Drug-eluting stents vs. Coronary-artery bypass grafting in multivessel coronary disease [J]. N Engl J Med.2008;358(4):331-341.
10. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB. Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents [J]. N Engl J Med.2007;356(10):998-1008.
11. Roiron C, Sanchez P, Bouzamondo A, Lechat P, Montalescot G. Drug eluting stents:An updated meta-analysis of randomised controlled trials [J]. Heart. 2006;92(5):641-649.
12. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery [J]. N Engl J Med.2003;349(14):1315-1323.
13. Meliga E, Garcia-Garcia HM, Kukreja N, Daemen J, Tanimoto S, Ramcharitar S, van Mieghem CA, Sianos G, van der Ent M, van der Giessen WJ, de Feyter P, van Domburg R, Serruys PW. Chronic total occlusion treatment in post-cabg patients: Saphenous vein graft versus native vessel recanalization-long-term follow-up in the drug-eluting stent era [J]. Catheter Cardiovasc Interv.2007;70(1):21-25.
14. 胡盛寿.正值“复合”(hybrid)技术的时代[J].中华心血管病杂志.2008；36(1)：1-2.
15. Angelini GD, Wilde P, Salerno TA, Bosco G, Calafiore AM. Integrated left small thoracotomy and angioplasty for multivessel coronary artery revascularisation [J]. Lancet.1996;347(9003):757-758.
16. Kon ZN, Brown EN, Tran R, Joshi A, Reicher B, Grant MC, Kallam S, Burris N, Connerney I, Zimrin D, Poston RS. Simultaneous hybrid coronary revascularization reduces postoperative morbidity compared with results from conventional off-pump coronary artery bypass [J]. J Thorac Cardiovasc Surg. 2008;135(2):367-375.
17. Katz MR, Van Praet F, de Canniere D, Murphy D, Siwek L, Seshadri-Kreaden U, Friedrich G, Bonatti J. Integrated coronary revascularization:Percutaneous coronary intervention plus robotic totally endoscopic coronary artery bypass [J]. Circulation.2006; 114(1 Suppl):I473-476.
18. Reicher B, Poston RS, Mehra MR, Joshi A, Odonkor P, Kon Z, Reyes PA, Zimrin DA. Simultaneous "Hybrid" Percutaneous coronary intervention and minimally invasive surgical bypass grafting:Feasibility, safety, and clinical outcomes [J]. Am Heart J.2008;155(4):661-667.
19. Davidavicius G, Van Praet F, Mansour S, Casselman F, Bartunek J, Degrieck I, Wellens F, De Geest R, Vanermen H, Wijns W, De Bruyne B. Hybrid revascularization strategy:A pilot study on the association of robotically enhanced minimally invasive direct coronary artery bypass surgery and fractional-flow-reserve-guided percutaneous coronary intervention [J]. Circulation.2005; 112(9 Suppl):I317-322.
20. 郑哲,胡盛寿,周玉燕.电视胸腔镜辅助下微创冠状动脉旁路移植术临床及随访结果[J].中华胸心血管外科杂志.2006；22(1)：52-53.
21. 胡盛寿,高润霖,郑哲,徐波.Hybrid技术治疗多支病变冠状动脉粥样硬化性心脏病[J].中国胸心血管外科临床杂志.2000；7(4)：273-274.
22. 赵强,夏利民,陈安清,王哲,徐德民.杂交技术在冠状动脉外科中的应用[J].中国微创外科杂志.2006；6(6)：421-423.
23. 王东进,邵峻,梁雨露,武忠,潘俊.胸腔镜辅助下冠状动脉旁路移植术与介入联合治疗冠心病多支病变七例 [J].中华心血管病杂志2006；34(3)：247-248.
24. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB, Jr., Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT. Efficacy and safety of edifoligide, an e2f transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: Prevent iv:A randomized controlled trial [J]. JAMA.2005;294(19):2446-2454.
25. Zhao DX, Leacche M, Balaguer JM, Boudoulas KD, Damp JA, Greelish JP, Byrne JG, Ahmad RM, Ball SK, Cleator JH, Deegan RJ, Eagle SS, Fong PP, Fredi JL, Hoff SJ, Jennings HS,3rd, McPherson JA, Piana RN, Pretorius M, Robbins MA, Slosky DA, Thompson A. Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/operating room [J]. J Am Coll Cardiol.2009;53(3):232-241.
26. Riess FC, Schofer J, Kremer P, Riess AG, Bergmann H, Moshar S, Mathey D, Bleese N. Beating heart operations including hybrid revascularization:Initial experiences [J]. Ann Thorac Surg.1998;66(3):1076-1081.
27. Byrne JG, Leacche M, Vaughan DE, Zhao DX. Hybrid cardiovascular procedures [J]. JACC Cardiovasc Interv.2008;1l(5):459-468.
28. Lloyd CT, Calafiore AM, Wilde P, Ascione R, Paloscia L, Monk CR, Angelini GD. Integrated left anterior small thoracotomy and angioplasty for coronary artery revascularization [J]. Ann Thorac Surg.1999;68(3):908-911; discussion 911-902.
29. Isomura T, Suma H, Horii T, Sato T, Kobashi T, Kanemitsu H. Minimally invasive coronary artery revascularization:Off-pump bypass grafting and the hybrid procedure [J]. Ann Thorac Surg.2000;70(6):2017-2022.
30. de Canniere D, Jansens JL, Goldschmidt-Clermont P, Barvais L, Decroly P, Stoupel E. Combination of minimally invasive coronary bypass and percutaneous transluminal coronary angioplasty in the treatment of double-vessel coronary disease:Two-year follow-up of a new hybrid procedure compared with “On-pump” Double bypass grafting [J]. Am Heart J.2001;142(4):563-570.
31. Presbitero P, Nicolini F, Maiello L, Franciosi G, Carcagni A, Milone F, Manasse E, Gallotti R. "Hybrid" Percutaneous and surgical coronary revascularization: Selection criteria from a single-center experience [J]. Ital Heart J. 2001;2(5):363-368.
32. Cisowski M, Morawski W, Drzewiecki J, Kruczak W, Toczek K, Bis J, Bochenek A. Integrated minimally invasive direct coronary artery bypass grafting and angioplasty for coronary artery revascularization [J]. Eur J Cardiothorac Surg. 2002;22(2):261-265.
33. Stahl KD, Boyd WD, Vassiliades TA, Karamanoukian HL. Hybrid robotic coronary artery surgery and angioplasty in multivessel coronary artery disease [J]. Ann Thorac Surg.2002;74(4):S1358-1362.
34. Lewis BS, Porat E, Halon DA, Ammar R, Flugelman MY, Khader N, Merdler A, Weisz G, Uretzky G Same-day combined coronary angioplasty and minimally invasive coronary surgery [J]. Am J Cardiol.1999;84(10):1246-1247, A1248.
35. Wittwer T, Cremer J, Klima U, Wahlers T, Haverich A. Myocardial "Hybrid" Revascularization:Intermediate results of an alternative approach to multivessel coronary artery disease [J]. J Thorac Cardiovasc Surg.1999; 118(4):766-767.
36. Riess FC, Bader R, Kremer P, Kuhn C, Kormann J, Mathey D, Moshar S, Tuebler T, Bleese N, Schofer J. Coronary hybrid revascularization from January 1997 to January 2001:A clinical follow-up [J]. Ann Thorac Surg.2002;73(6):1849-1855.
37. Zenati M, Cohen HA, Griffith BP. Alternative approach to multivessel coronary disease with integrated coronary revascularization [J]. J Thorac Cardiovasc Surg. 1999;117(3):439-444; discussion 444-436.
38. Us MH, Basaran M, Yilmaz M, Yaymaci B, Ulusoy E, Sanioglu S, Ozbek C, Arslan Y, Pocan S, Yilmaz AT. Hybrid coronary revascularization in high-risk patients [J]. Tex Heart Inst J.2006;33(4):458-462.
39. Gilard M, Bezon E, Cornily JC, Mansourati J, Mondine P, Barra JA, Boschat J. Same-day combined percutaneous coronary intervention and coronary artery surgery [J]. Cardiology.2007;108(4):363-367.
40. Lee MS, Wilentz JR, Makkar RR, Singh V, Nero T, Swistel D, Belsey SJ, Simon C, Rametta S, DeRose J. Hybrid revascularization using percutaneous coronary intervention and robotically assisted minimally invasive direct coronary artery bypass surgery [J]. J Invasive Cardiol.2004; 16(8):419-425.
41. Kiaii B, McClure RS, Kostuk WJ, Rayman R, Swinamer S, Dobkowski WB, Novick RJ. Concurrent robotic hybrid revascularization using an enhanced operative suite [J]. Chest.2005;128(6):4046-4048.
42. Vassiliades TA, Jr., Douglas JS, Morris DC, Block PC, Ghazzal Z, Rab ST, Cates CU. Integrated coronary revascularization with drug-eluting stents:Immediate and seven-month outcome [J]. J Thorac Cardiovasc Surg.2006;131(5):956-962.
43. Bonatti J, Schachner T, Bonaros N, Jonetzko P, Ohlinger A, Ruetzler E, Kolbitsch C, Feuchtner G, Laufer G, Pachinger O, Friedrich G. Simultaneous hybrid coronary revascularization using totally endoscopic left internal mammary artery bypass grafting and placement of rapamycin eluting stents in the same interventional session. The combination pilot study [J]. Cardiology. 2007;110(2):92-95.
44. Kiaii B, McClure RS, Stewart P, Rayman R, Swinamer SA, Suematsu Y, Fox S, Higgins J, Albion C, Kostuk WJ, Almond D, Sridhar K, Teefy P, Jablonsky G, Diamantouros P, Dobkowski WB, Jones P, Bainbridge D, Iglesias I, Murkin J, Cheng D, Novick RJ. Simultaneous integrated coronary artery revascularization with long-term angiographic follow-up [J]. J Thorac Cardiovasc Surg. 2008;136(3):702-708.
45. Gao C, Yang M, Wu Y, Wang G, Xiao C, Liu H, Lu C. Hybrid coronary revascularization by endoscopic robotic coronary artery bypass grafting on beating heart and stent placement [J]. Ann Thorac Surg.2009;87(3):737-741.
46. Fonger JD. Integrated myocardial revascularization [J]. Eur J Cardiothorac Surg. 1999;16 Suppl 2:S12-17.
47. 郑哲,胡盛寿,宋云虎,孙寒松,王水云,蒋世良,徐仲英.杂交(hybrid)手术治疗冠心病多支病变合并房间隔缺损[J].中国微创外科杂志2005；5(12)：978-979.
48. Cohen HA, Zenati M, Smith AJ, Lee JS, Chough S, Jafar Z, Counihan P, Izzo M, Burchenal JE, Feldman AM, Griffith B. Feasibility of combined percutaneous transluminal angioplasty and minimally invasive direct coronary artery bypass in patients with multivessel coronary artery disease [J]. Circulation. 1998;98(11):1048-1050.
49. Wittwer T, Cremer J, Boonstra P, Grandjean J, Mariani M, Mugge A, Drexler H, den Heijer P, Leitner ER, Hepp A, Wehr M, Haverich A. Myocardial "Hybrid" Revascularisation with minimally invasive direct coronary artery bypass grafting combined with coronary angioplasty:Preliminary results of a multicentre study [J]. Heart.2000;83(1):58-63.
50. Hu SS, Gao RL, Gao PX, Li LH, Xiong H, Xu B, Yang YJ, Yuan JQ, Zheng Z. [efficacy of one-stop hybrid revascularization for treatment of unprotected left main coronary artery disease.] [J]. Zhonghua Xin Xue Guan Bing Za Zhi. 2010;38(1):23-26.
51. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Jr., Chavey WE,2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC, Jr., Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B. Acc/aha 2007 guidelines for the management of patients with unstable angina/non-st-elevation myocardial infarction:A report of the american college of cardiology/american heart association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-st-elevation myocardial infarction) developed in collaboration with the american college of emergency physicians, the society for cardiovascular angiography and interventions, and the society of thoracic surgeons endorsed by the american association of cardiovascular and pulmonary rehabilitation and the society for academic emergency medicine [J]. J Am Coll Cardiol.2007;50(7):el-e157.
52. Murphy GJ, Bryan AJ, Angelini GD. Hybrid coronary revascularization in the era of drug-eluting stents [J]. Ann Thorac Surg.2004;78(5):1861-1867.
53. Gao P, Xiong H, Zheng Z, Li L, Gao R, Hu SS. Evaluation of antiplatelet effects of a modified protocol by platelet aggregation in patients undergoing "One-stop" Hybrid coronary revascularization [J]. Platelets.2010;21(3):183-190.
54. 徐仲英,胡海波,黄连军,赵世华,凌坚,郑宏,蒋世良,沈向东.介入技术与外科手术联合治疗复杂先天性心脏病的临床研究[J].中华心血管病杂志.2004；32(2)：144-147.
55. 胡盛寿,李守军,张浩,孙寒松,沈向东,王浩,蒋世良.杂交(hybrid)手术在复杂性先天性心脏病治疗中的初步应用[J].中国微创外科杂志.2005；5(12)：976-977.
56. 胡盛寿,李守军,张浩,王旭,王浩,晏馥霞,蒋世良,李永清.“杂交’’技术治疗新生儿室间隔完整的肺动脉闭锁[J].中华胸心血管外科杂志.2006；22(6)：376-377.
57. Zhang H, Li SJ, Li YQ, Wang H, Hu SS. Hybrid procedure for the neonatal management of pulmonary atresia with intact ventricular septum [J]. J Thorac Cardiovasc Surg.2007;133(6):1654-1656.
58. 李守军,胡盛寿,张浩,沈向东,闫军,王旭,徐仲英,邓喜成,李永青.一站式“杂交”技术治疗婴幼儿先天性心脏病[J].中华心血管病杂志.2009；37(11)：986-989.
59. 郑哲,李守军,胡盛寿,王德,刘志刚,张瑛,徐仲英,胡海波.分期和“一站式"hybrid手术治疗法洛四联症合并体肺动脉侧支血管形成的疗效对比[J].中国胸心血管外科临床杂志.2009；16(4)：250-253.
60. 曾筝,张戈军,蒋世良,黄连军,崔炜,张岩,张少雄,鲍菲,戴汝平.体肺侧枝血管栓塞术在复杂先天性心脏病治疗中的作用[J].中华放射学杂志.1998；32(8)：519-521.
61. 方敏华,朱洪玉,汪曾炜,张仁福,王辉山,李新民.法洛四联症合并大的体肺侧枝动脉手术矫治[J].中华外科杂志.2005；43(22)：1437—1440.
62. 王树水,张智伟,庄建,陈欣欣,钱明阳,李渝芬.心脏外科手术与介入性心导管术镶嵌治疗小儿先天性心脏病[J].中华胸心血管外科杂志.2005；21(2)：82-84.
63. Fishberger SB, Bridges ND, Keane JF, Hanley FL, Jonas RA, Mayer JE, Castaneda AR, Lock JE. Intraoperative device closure of ventricular septal defects [J]. Circulation.1993;88(5 Pt 2):Ⅱ 205-209.
64. Okubo M, Benson LN, Nykanen D, Azakie A, Van Arsdell G, Coles J, Williams WG. Outcomes of intraoperative device closure of muscular ventricular septal defects [J]. Ann Thorac Surg.2001;72(2):416-423.
65. Bacha EA, Cao QL, Galantowicz ME, Cheatham JP, Fleishman CE, Weinstein SW, Becker PA, Hill SL, Koenig P, Alboliras E, Abdulla R, Starr JP, Hijazi ZM. Multicenter experience with perventricular device closure of muscular ventricular septal defects [J]. Pediatr Cardiol.2005;26(2):169-175.
66. Amin Z, Berry JM, Foker JE, Rocchini AP, Bass JL. Intraoperative closure of muscular ventricular septal defect in a canine model and application of the technique in a baby [J]. J Thorac Cardiovasc Surg.1998;115(6):1374-1376.
67. 李巅远,闫军,李守军,晏馥霞,李立环,魏以帧,郑哲,刘志刚,崔彬,陶天富,胡盛寿.三种不同微创技术与经典外科技术治疗房间隔缺损的临床对比 研究[J].中国胸心血管外科临床杂志.2009；16(1)：31-35.
68. 胡海波,凌坚,张戈军,蒋世良,郑宏,徐仲英,赵世华,黄连军,王云.法乐四联症外科根治术后残余右室流出道梗阻的介入治疗[J].中华分子心脏病学杂志.2008；8(4)：231-232.
69. Holzer RJ, Sisk M, Chisolm JL, Hill SL, Olshove V, Phillips A, Cheatham JP, Galantowicz M. Completion angiography after cardiac surgery for congenital heart disease:Complementing the intraoperative imaging modalities [J]. Pediatr Cardiol.2009;30(8):1075-1082.
70. Dake MD, Miller DC, Semba CP, Mitchell RS, Walker PJ, Liddell RP. Transluminal placement of endovascular stent-grafts for the treatment of descending thoracic aortic aneurysms [J]. N Engl J Med. 1994;331(26):1729-1734.
71. Xydas S, Wei B, Takayama H, Russo M, Bacchetta M, Smith CR, Stewart A. Use of carotid-subclavian arterial bypass and thoracic endovascular aortic repair to minimize cerebral ischemia in total aortic arch reconstruction [J]. J Thorac Cardiovasc Surg.2010;139(3):717-722; discussion 722.
72. Ucak A, Onan B, Inan BK, Temizkan V, Ugur M, Yilmaz AT. Hybrid repair of an acute type b dissection with subclavian-to-subclavian bypass and stent-grafting [J]. J Card Surg.2010
73. Patel HJ, Upchurch GR, Jr., Eliason JL, Criado E, Rectenwald J, Williams DM, Deeb GM. Hybrid debranching with endovascular repair for thoracoabdominal aneurysms:A comparison with open repair [J]. Ann Thorac Surg. 2010;89(5):1475-1481.
74. Donas KP, Lachat M, Rancic Z, Oberkofler C, Pfammatter T, Guber I, Veith FJ, Mayer D. Early and midterm outcome of a novel technique to simplify the hybrid procedures in the treatment of thoracoabdominal and pararenal aortic aneurysms [J]. J Vasc Surg.2009;50(6):1280-1284.
75. Bockler D, Nassar J, Kotelis D, Geisbusch P, Hyhlik-Durr A, Von Tengg-Kobligk H, Weber TF, Schumacher H. Hybrid approach for arch and thoracoabdominal pathologies [J]. J Cardiovasc Surg (Torino).2009;50(4):461-474.
76. Black SA, Wolfe JH, Clark M, Hamady M, Cheshire NJ, Jenkins MP. Complex thoracoabdominal aortic aneurysms:Endovascular exclusion with visceral revascularization [J]. J Vasc Surg.2006;43(6):1081-1089; discussion 1089.
77. Biasi L, Ali T, Loosemore T, Morgan R, Loftus I, Thompson M. Hybrid repair of complex thoracoabdominal aortic aneurysms using applied endovascular strategies combined with visceral and renal revascularization [J]. J Thorac Cardiovasc Surg.2009;138(6):1331-1338.
78. Patel R, Conrad MF, Paruchuri V, Kwolek CJ, Chung TK, Cambria RP. Thoracoabdominal aneurysm repair:Hybrid versus open repair [J]. J Vasc Surg. 2009;50(1):15-22.
79. Kato M, Ohnishi K, Kaneko M, Ueda T, Kishi D, Mizushima T, Matsuda H. New graft-implanting method for thoracic aortic aneurysm or dissection with a stented graft [J]. Circulation.1996;94(9 Suppl):Ⅱ 188-193.
80. Brueck M, Heidt MC, Szente-Varga M, Bandorski D, Kramer W, Vogt PR. Hybrid treatment for complex aortic problems combining surgery and stenting in the integrated operating theater [J]. J Interv Cardiol.2006;19(6):539-543.
81. 田川,常谦,孙立忠,于存涛,郑军,朱俊明,刘永民,董超.应用象鼻技术治疗主动脉夹层和主动脉瘤 [J].中华胸心血管外科杂志2007；23(3)：178-180.
82. Cox JL. The surgical treatment of atrial fibrillation. Iv. Surgical technique [J]. J Thorac Cardiovasc Surg.1991;101(4):584-592.
83. Ad N. The cox-maze procedure:History, results, and predictors for failure [J]. J Interv Card Electrophysiol.2007;20(3):65-71.
84. Choi JI, Pak HN, Kim YH. Hybrid epicardial and endocardial catheter ablation in a patient with atrial fibrillation and suspicious left atrial thrombus [J]. Circ J. 2009;73(2):384-387.
85. Machino T, Tada H, Sekiguchi Y, Tanaka Y, Naito S, Yamasaki H, Arimoto T, Igarashi M, Kuroki K, Seo Y, Watanabe S, Hoshizaki H, Oshima S, Taniguchi K, Aonuma K. Hybrid therapy of radiofrequency catheter ablation and percutaneous transvenous mitral commissurotomy in patients with atrial fibrillation and mitral stenosis [J]. J Cardiovasc Electrophysiol.2009
86. Skanes AC, Klein GJ, Guiraudon G, Menkis AH, Jones DL, Krahn AD, Yee R. Hybrid approach for minimally-invasive operative therapy of arrhythmias [J]. J Interv Card Electrophysiol.2003;9(2):289-294.
87. Borger MA, Fremes SE, Weisel RD, Cohen G, Rao V, Lindsay TF, Naylor CD. Coronary bypass and carotid endarterectomy:Does a combined approach increase risk? Ametaanalysis [J]. Ann Thorac Surg.1999;68(1):14-20; discussion 21.
88. Salasidis GC, Latter DA, Steinmetz OK, Blair JF, Graham AM. Carotid artery duplex scanning in preoperative assessment for coronary artery revascularization: The association between peripheral vascular disease, carotid artery stenosis, and stroke [J]. J Vasc Surg.1995;21(1):154-160; discussion 161-152.
89. Das SK, Brow TD, Pepper J. Continuing controversy in the management of concomitant coronary and carotid disease:An overview [J]. Int J Cardiol. 2000;74(1):47-65.
90. Mathias KD. Angioplasty and stenting for carotid lesions:An argument for [J]. Adv Surg.1999;32:225-243.
91. Lopes DK, Mericle RA, Lanzino Q Wakhloo AK, Guterman LR, Hopkins LN. Stent placement for the treatment of occlusive atherosclerotic carotid artery disease in patients with concomitant coronary artery disease [J]. J Neurosurg. 2002;96(3):490-496.
92. Versaci F, Del Giudice C, Scafuri A, Zeitani J, Gandini R, Nardi P, Salvati A, Pampana E, Sebastiano F, Romagnoli A, Simonetti G, Chiariello L. Sequential hybrid carotid and coronary artery revascularization:Immediate and mid-term results [J]. Ann Thorac Surg.2007;84(5):1508-1513; discussion 1513-1504.
93. Masroor S, Berkowitz R, Nejad K, Alexander JC. Hybrid percutaneous coronary intervention and minimally invasive reoperative mitral valve surgery [J]. J Card Surg.2009;24(2):191-193.
94. Byrne JG, Leacche M, Unic D, Rawn JD, Simon DI, Rogers CD, Cohn LH. Staged initial percutaneous coronary intervention followed by valve surgery ("Hybrid approach") for patients with complex coronary and valve disease [J]. J Am Coll Cardiol.2005;45(1):14-18.
2. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB. Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents [J]. N Engl J Med.2007;356(10):998-1008.
3. Abbott JD, Voss MR, Nakamura M, Cohen HA, Selzer F, Kip KE, Vlachos HA, Wilensky RL, Williams DO. Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice:Findings from the national heart, lung, and blood institute dynamic registry [J]. J Am Coll Cardiol.2007;50(21):2029-2036.
4. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Stahle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease [J]. N Engl J Med.2009;360(10):961-72. Epub 2009 Feb 18.
5. Coronary artery surgery study (cass):A randomized trial of coronary artery bypass surgery. Survival data [J]. Circulation.1983;68(5):939-950.
6. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The bypass angioplasty revascularization investigation (bari) investigators [J]. N Engl J Med.1996;335(4):217-225.
7. Angelini GD, Wilde P, Salerno TA, Bosco G, Calafiore AM. Integrated left small thoracotomy and angioplasty for multivessel coronary artery revascularisation [J]. Lancet.1996;347(9003):757-758.
8. Hu SS. One-stop hybrid approach for cardiovascular disease:From conception to practice [J]. Ann Thorac Cardiovasc Surg.2008;14(6):345-346.
9. Fonger JD. Integrated myocardial revascularization [J]. Eur J Cardiothorac Surg.1999;16 Suppl 2:S12-17.
10. Kpodonu J, Raney A. The cardiovascular hybrid room a key component for hybrid interventions and image guided surgery in the emerging specialty of cardiovascular hybrid surgery [J]. Interact Cardiovasc Thorac Surg. 2009;9(4):688-692.
11. Field ML, Sammut J, Kuduvalli M, Oo A, Rashid A. Hybrid theatres:Nicety or necessity? [J]. J R Soc Med.2009;102(3):92-97.
12.高培显,熊辉,胡盛寿.杂交(hybrid)技术治疗冠状动脉多支病变：进展和争议[J].中华胸心血管外科杂志.2009；25(4)：274-276
13.胡盛寿.正值“复合”(hybrid)技术的时代[J].中华心血管病杂志.2008；36(1)：1-2.
14.胡盛寿,高润霖,郑哲,徐波.Hybrid技术治疗多支病变冠状动脉粥样硬化性心脏病[J].中国胸心血管外科临床杂志.2000；7(4)：273-274.
15. Gao R, Hu S, Zheng Z, Yang Y, Qiao S, Qin X, Yao M, Liu H, Jilin Chen, Xu B. "Hybrid" Revascularization:Vi deo-thoracoscopy assisted midcab combined with angioplasty [J]. J Invasive Cardiol.2001;13(3):257-259.
16. Kiaii B, McClure RS, Kostuk WJ, Rayman R, Swinamer S, Dobkowski WB, Novick RJ. Concurrent robotic hybrid revascularization using an enhanced operative suite [J]. Chest.2005;128(6):4046-4048.
17. Kon ZN, Brown EN, Tran R, Joshi A, Reicher B, Grant MC, Kallam S, Burris N, Connerney I, Zimrin D, Poston RS. Simultaneous hybrid coronary revascularization reduces postoperative morbidity compared with results from conventional off-pump coronary artery bypass [J]. J Thorac Cardiovasc Surg. 2008;135(2):367-375.
18. Reicher B, Poston RS, Mehra MR, Joshi A, Odonkor P, Kon Z, Reyes PA, Zimrin DA. Simultaneous "Hybrid" Percutaneous coronary intervention and minimally invasive surgical bypass grafting:Feasibility, safety, and clinical outcomes [J]. Am Heart J.2008;155(4):661-667.
19. Zhao DX, Leacche M, Balaguer JM, Boudoulas KD, Damp JA, Greelish JP, Byrne JG, Ahmad RM, Ball SK, Cleator JH, Deegan RJ, Eagle SS, Fong PP, Fredi JL, Hoff SJ, Jennings HS,3rd, McPherson JA, Piana RN, Pretorius M, Robbins MA, Slosky DA, Thompson A. Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/operating room [J]. J Am Coll Cardiol.2009;53(3):232-241.
20. Stahl KD, Boyd WD, Vassiliades TA, Karamanoukian HL. Hybrid robotic coronary artery surgery and angioplasty in multivessel coronary artery disease [J]. Ann Thorac Surg.2002;74(4):S1358-1362.
21. Murphy GJ, Bryan AJ, Angelini GD. Hybrid coronary revascularization in the era of drug-eluting stents [J]. Ann Thorac Surg.2004;78(5):1861-1867.
22. Katz MR, Van Praet F, de Canniere D, Murphy D, Siwek L, Seshadri-Kreaden U, Friedrich G, Bonatti J. Integrated coronary revascularization:Percutaneous coronary intervention plus robotic totally endoscopic coronary artery bypass [J]. Circulation.2006;114(1 Suppl):I473-476.
23. Riess FC, Schofer J, Kremer P, Riess AG, Bergmann H, Moshar S, Mathey D, Bleese N. Beating heart operations including hybrid revascularization:Initial experiences [J]. Ann Thorac Surg.1998;66(3):1076-1081.
24. Cohen HA, Zenati M, Smith AJ, Lee JS, Chough S, Jafar Z, Counihan P, Izzo M, Burchenal JE, Feldman AM, Griffith B. Feasibility of combined percutaneous transluminal angioplasty and minimally invasive direct coronary artery bypass in patients with multivessel coronary artery disease [J]. Circulation.1998;98(11):1048-1050.
25. Riess FC, Bader R, Kremer P, Kuhn C, Kormann J, Mathey D, Moshar S, Tuebler T, Bleese N, Schofer J. Coronary hybrid revascularization from January 1997 to january 2001:A clinical follow-up [J]. Ann Thorac Surg. 2002;73(6):1849-1855.
26. Wittwer T, Cremer J, Boonstra P, Grandjean J, Mariani M, Mugge A, Drexler H, den Heijer P, Leitner ER, Hepp A, Wehr M, Haverich A. Myocardial "Hybrid" Revascularisation with minimally invasive direct coronary artery bypass grafting combined with coronary angioplasty:Preliminary results of a multicentre study [J]. Heart.2000;83(1):58-63.
27. 胡盛寿,高润霖,高培显,李立环,熊辉,徐波,杨跃进,袁晋青,郑哲.一站式复合血管重建技术治疗无保护左主干病变[J].中华心血管病杂志.2010；38(1)：23-26.
28. Niinami H, Ogasawara H, Suda Y, Takeuchi Y. Single-vessel revascularization with minimally invasive direct coronary artery bypass:Minithoracotomy or ministernotomy? [J]. Chest.2005;127(1):47-52.
29. Niinami H, Takeuchi Y, Ichikawa S, Suda Y. Partial median sternotomy as a minimal access for off-pump coronary artery bypass grafting:Feasibility of the lower-end sternal splitting approach [J]. Ann Thorac Surg. 2001;72(3):S1041-1045.
30. 马维国,孙寒松,胡盛寿,许建屏,吕锋,朱晓东.胸骨下段正中小切口直视冠状动脉旁路移植术 [J].中国胸心血管外科临床杂志2005；12(4)：240-243.
31. Oehlinger A, Bonaros N, Schachner T, Ruetzler E, Friedrich G, Laufer G, Bonatti J. Robotic endoscopic left internal mammary artery harvesting:What have we learned after 100 cases? [J]. Ann Thorac Surg.2007;83(3):1030-1034.
32. Kiaii B, McClure RS, Stitt L, Rayman R, Dobkowski WB, Jablonsky G, Novick RJ, Boyd WD. Prospective angiographic comparison of direct, endoscopic, and telesurgical approaches to harvesting the internal thoracic artery [J]. Ann Thorac Surg.2006;82(2):624-628.
33. Kappert U, Schneider J, Cichon R, Gulielmos V, Tugtekin SM, Nicolai J, Matschke K, Schueler S. Development of robotic enhanced endoscopic surgery for the treatment of coronary artery disease [J]. Circulation. 2001;104(12 Suppl 1):I102-107.
1. Moller CH, Penninga L, Wetterslev J, Steinbruchel DA, Gluud C. Clinical outcomes in randomized trials of off-vs. On-pump coronary artery bypass surgery:Systematic review with meta-analyses and trial sequential analyses [J]. Eur Heart J.2008;29(21):2601-2616.
2. Hannan EL, Wu C, Smith CR, Higgins RS, Carlson RE, Culliford AT, Gold JP, Jones RH. Off-pump versus on-pump coronary artery bypass graft surgery: Differences in short-term outcomes and in long-term mortality and need for subsequent revascularization [J]. Circulation.2007; 116(10):1145-1152.
3. Li Y, Zheng Z, Hu S. Early and long-term outcomes in the elderly: Comparison between off-pump and on-pump techniques in 1191 patients undergoing coronary artery bypass grafting [J]. J Thorac Cardiovasc Surg. 2008;136(3):657-664.
4. Hu S, Zheng Z, Yuan X, Wang W, Song Y, Sun H, Xu J. Increasing long-term major vascular events and resource consumption in patients receiving off-pump coronary artery bypass:A single-center prospective observational study [J]. Circulation.2010; 121(16):1800-1808.
5. Hu SS. One-stop hybrid approach for cardiovascular disease:From conception to practice [J]. Ann Thorac Cardiovasc Surg.2008;14(6):345-346
6.胡盛寿.正值“复合”(hybrid)技术的时代[J].中华心血管病杂志.2008；36(1)：1-2.
7. Reicher B, Poston RS, Mehra MR, Joshi A, Odonkor P, Kon Z, Reyes PA, Zimrin DA. Simultaneous "Hybrid" Percutaneous coronary intervention and minimally invasive surgical bypass grafting:Feasibility, safety, and clinical outcomes [J]. Am Heart J.2008; 155(4):661-667.
8. Kon ZN, Brown EN, Tran R, Joshi A, Reicher B, Grant MC, Kallam S, Burris N, Connerney I, Zimrin D, Poston RS. Simultaneous hybrid coronary revascularization reduces postoperative morbidity compared with results from conventional off-pump coronary artery bypass [J]. J Thorac Cardiovasc Surg. 2008;135(2):367-375.
9. Kiaii B, McClure RS, Stewart P, Rayman R, Swinamer SA, Suematsu Y, Fox S, Higgins J, Albion C, Kostuk WJ, Almond D, Sridhar K, Teefy P, Jablonsky G, Diamantouros P, Dobkowski WB, Jones P, Bainbridge D, Iglesias I, Murkin J,
Cheng D, Novick RJ. Simultaneous integrated coronary artery revascularization with long-term angiographic follow-up [J]. J Thorac Cardiovasc Surg.2008;136(3):702-708.
10. Bonatti J, Schachner T, Bonaros N, Jonetzko P, Ohlinger A, Ruetzler E, Kolbitsch C, Feuchtner G, Laufer G, Pachinger O, Friedrich G. Simultaneous hybrid coronary revascularization using totally endoscopic left internal mammary artery bypass grafting and placement of rapamycin eluting stents in the same interventional session. The combination pilot study [J]. Cardiology. 2008;110(2):92-95.
11. Zhao DX, Leacche M, Balaguer JM, Boudoulas KD, Damp JA, Greelish JP, Byrne JG, Ahmad RM, Ball SK, Cleator JH, Deegan RJ, Eagle SS, Fong PP, Fredi JL, Hoff SJ, Jennings HS,3rd, McPherson JA, Piana RN, Pretorius M, Robbins MA, Slosky DA, Thompson A. Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/operating room [J]. J Am Coll Cardiol.2009;53(3):232-241.
12. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects [J]. Biometrika.1983;70(1):41.
13. 赵守军,张勇,汪萱怡,高燕宁.均衡组间差异的有效方法：倾向评分[J].中华流行病学杂志.2003；24(6)：516-519.
14. Blackstone EH. Comparing apples and oranges [J]. J Thorac Cardiovasc Surg. 2002;123(1):8-15.
15. Rubin DB. The design versus the analysis of observational studies for causal effects:Parallels with the design of randomized trials [J]. Stat Med. 2007;26(1):20-36.
16. Rubin DB. Estimating causal effects from large data sets using propensity scores [J]. Ann Intern Med.1997; 127(8 Pt 2):757-763.
17. Synnergren MJ, Ekroth R, Oden A, Rexius H, Wiklund L. Incomplete revascularization reduces survival benefit of coronary artery bypass grafting: Role of off-pump surgery [J]. J Thorac Cardiovasc Surg.2008;136(1):29-36.
18. Lim E, Drain A, Davies W, Edmonds L, Rosengard BR. A systematic review of randomized trials comparing revascularization rate and graft patency of off-pump and conventional coronary surgery [J]. J Thorac Cardiovasc Surg. 2006;132(6):1409-1413.
19. Takagi H, Tanabashi T, Kawai N, Kato T, Umemoto T. Off-pump coronary artery bypass sacrifices graft patency:Meta-analysis of randomized trials [J]. J Thorac Cardiovasc Surg.2007;133(1):e2-3.
20. Parolari A, Camera M, Alamanni F, Naliato M, Polvani GL, Agrifoglio M, Brambilla M, Biancardi C, Mussoni L, Biglioli P, Tremoli E. Systemic inflammation after on-pump and off-pump coronary bypass surgery:A one-month follow-up [J]. Ann Thorac Surg.2007;84(3):823-828.
21. van Dijk D, Spoor M, Hijman R, Nathoe HM, Borst C, Jansen EW, Grobbee DE, de Jaegere PP, Kalkman CJ. Cognitive and cardiac outcomes 5 years after off-pump vs on-pump coronary artery bypass graft surgery [J]. JAMA. 2007;297(7):701-708.
22. Van Dijk D, Jansen EW, Hijman R, Nierich AP, Diephuis JC, Moons KG, Lahpor JR, Borst C, Keizer AM, Nathoe HM, Grobbee DE, De Jaegere PP, Kalkman CJ. Cognitive outcome after off-pump and on-pump coronary artery bypass graft surgery:A randomized trial [J]. JAMA.2002;287(11):1405-1412.
23. Angelini GD, Wilde P, Salerno TA, Bosco G, Calafiore AM. Integrated left small thoracotomy and angioplasty for multivessel coronary artery revascularisation [J]. Lancet.1996;347(9003):757-758.
24. Lev-Ran O, Braunstein R, Sharony R, Kramer A, Paz Y, Mohr R, Uretzky G. No-touch aorta off-pump coronary surgery:The effect on stroke [J]. J Thorac Cardiovasc Surg.2005;129(2):307-313.
25. 马维国,孙寒松,胡盛寿,许建屏,吕锋,朱晓东.胸骨下段正中小切口直视冠状动脉旁路移植术[J].中国胸心血管外科临床杂志.2005；12(4)：240-243.
26. Niinami H, Ogasawara H, Suda Y, Takeuchi Y. Single-vessel revascularization with minimally invasive direct coronary artery bypass:Minithoracotomy or ministernotomy? [J]. Chest.2005;127(1):47-52.
27. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB, Jr., Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT. Efficacy and safety of edifoligide, an e2f transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery:Prevent iv:A randomized controlled trial [J]. JAMA. 2005;294(19):2446-2454.
28. Mack MJ. Intraoperative coronary graft assessment [J]. Curr Opin Cardiol. 2008;23(6):568-572.
29. D'Ancona G, Bartolozzi F, Bogers AJ, Pilato M, Parrinello M, Kappetein AP. Intraoperative graft patency verification in coronary artery surgery:Modern diagnostic tools [J]. J Cardiothorac Vasc Anesth.2009;23(2):232-238.
30. Wittwer T, Cremer J, Boonstra P, Grandjean J, Mariani M, Mugge A, Drexler H, den Heijer P, Leitner ER, Hepp A, Wehr M, Haverich A. Myocardial "Hybrid" Revascularisation with minimally invasive direct coronary artery bypass grafting combined with coronary angioplasty:Preliminary results of a multicentre study [J]. Heart.2000;83(1):58-63.
1. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, Davis K, Killip T, Passamani E, Norris R, et al. Effect of coronary artery bypass graft surgery on survival:Overview of 10-year results from randomised trials by the coronary artery bypass graft surgery trialists collaboration [J]. Lancet. 1994;344(8922):563-570.
2. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Jr., Chavey WE,2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC, Jr., Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B. Acc/aha 2007 guidelines for the management of patients with unstable angina/non-st-elevation myocardial infarction:A report of the american college of cardiology/american heart association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-st-elevation myocardial infarction) developed in collaboration with the american college of emergency physicians, the society for cardiovascular angiography and interventions, and the society of thoracic surgeons endorsed by the american association of cardiovascular and pulmonary rehabilitation and the society for academic emergency medicine [J]. J Am Coll Cardiol.2007;50(7):el-e157.
3.胡盛寿,张浩.微创心脏外科学的概念和发展[J].中国微创外科杂志.2006；6(6)：404-406.
4. Angelini GD, Wilde P, Salerno TA, Bosco G, Calafiore AM. Integrated left small thoracotomy and angioplasty for multivessel coronary artery revascularisation [J]. Lancet.1996;347(9003):757-758.
5. Fonger JD. Integrated myocardial revascularization [J]. Eur J Cardiothorac Surg.1999;16 Suppl 2:S12-17.
6.胡盛寿,高润霖,郑哲,徐波.Hybrid技术治疗多支病变冠状动脉粥样硬化性心脏病[J].中国胸心血管外科临床杂志.2000；7(4)：273-274.
7.赵强,夏利民,陈安清,王哲,徐德民.杂交技术在冠状动脉外科中的应用[J].中国微创外科杂志.2006；6(6)：421-423.
8.王东进,邵峻,梁雨露,武忠,潘俊.胸腔镜辅助下冠状动脉旁路移植术与介入联合治疗冠心病多支病变七例[J]．中华心血管病杂志. 2006;34(3):247-248.
9. Kon ZN, Brown EN, Tran R, Joshi A, Reicher B, Grant MC, Kallam S, Burris N, Connerney I, Zimrin D, Poston RS. Simultaneous hybrid coronary revascularization reduces postoperative morbidity compared with results from conventional off-pump coronary artery bypass [J]. J Thorac Cardiovasc Surg. 2008;135(2):367-375.
10. Reicher B, Poston RS, Mehra MR, Joshi A, Odonkor P, Kon Z, Reyes PA, Zimrin DA. Simultaneous "Hybrid" Percutaneous coronary intervention and minimally invasive surgical bypass grafting:Feasibility, safety, and clinical outcomes [J]. Am Heart J.2008;155(4):661-667.
11. 胡盛寿.正值“复合”(hybrid)技术的时代[J].中华心血管病杂志.2008；36(1)：1-2.
12. 胡盛寿,张浩.微创心血管外科的一个全新概念--一站式杂交手术[J].中国微创外科杂志.2005；5(12)：975.
13. Reicher B, Poston RS, Mehra MR, Joshi A, Odonkor P, Kon Z, Reyes PA, Zimrin DA. Simultaneous "Hybrid" Percutaneous coronary intervention and minimally invasive surgical bypass grafting:Feasibility, safety, and clinical outcomes [J]. Am Heart J.2008;155(4):661-667.
14. Kiaii B, McClure RS, Stewart P, Rayman R, Swinamer SA, Suematsu Y, Fox S, Higgins J, Albion C, Kostuk WJ, Almond D, Sridhar K, Teefy P, Jablonsky G, Diamantouros P, Dobkowski WB, Jones P, Bainbridge D, Iglesias I, Murkin J, Cheng D, Novick RJ. Simultaneous integrated coronary artery revascularization with long-term angiographic follow-up [J]. J Thorac Cardiovasc Surg.2008;136(3):702-708.
15. Bonatti J, Schachner T, Bonaros N, Jonetzko P, Ohlinger A, Ruetzler E, Kolbitsch C, Feuchtner G, Laufer G, Pachinger O, Friedrich G. Simultaneous hybrid coronary revascularization using totally endoscopic left internal mammary artery bypass grafting and placement of rapamycin eluting stents in the same interventional session. The combination pilot study [J]. Cardiology. 2008;110(2):92-95.
16. Li Y, Zheng Z, Xu B, Zhang S, Li W, Gao R, Hu S. Comparison of drug-eluting stents and coronary artery bypass surgery for the treatment of multivessel coronary disease:Three-year follow-up results from a single institution [J]. Circulation.2009;119(15):2040-2050.
17. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents [J]. N Engl J Med.2007;356(10):1020-1029.
18. Pinto Slottow TL, Waksman R. Overview of the 2006 food and drug administration circulatory system devices panel meeting on drug-eluting stent thrombosis [J]. Catheter Cardiovasc Interv.2007;69(7):1064-1074.
19. Goldman S, Zadina K, Moritz T, Ovitt T, Sethi G, Copeland JG, Thottapurathu L, Krasnicka B, Ellis N, Anderson RJ, Henderson W. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery:Results from a department of veterans affairs cooperative study [J]. J Am Coll Cardiol.2004;44(11):2149-2156.
20. Aziz O, Rao C, Panesar SS, Jones C, Morris S, Darzi A, Athanasiou T. Meta-analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery [J]. BMJ.2007;334(7594):617.
21. Zimrin D, Reyes PA, Reicher B, Poston RS. A hybrid alternative for high risk left main disease [J]. Catheter Cardiovasc Interv.2007;69(1):123-127.
22. Valgimigli M, Malagutti P, Rodriguez-Granillo GA, Garcia-Garcia HM, Polad J, Tsuchida K, Regar E, Van der Giessen WJ, de Jaegere P, De Feyter P, Serruys PW. Distal left main coronary disease is a major predictor of outcome in patients undergoing percutaneous intervention in the drug-eluting stent era: An integrated clinical and angiographic analysis based on the rapamycin-eluting stent evaluated at rotterdam cardiology hospital (research) and taxus-stent evaluated at rotterdam cardiology hospital (t-search) registries [J]. J Am Coll Cardiol.2006;47(8):1530-1537.
23. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Jr., Chavey WE,2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC, Jr., Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B. Acc/aha 2007 guidelines for the management of patients with unstable angina/non st-elevation myocardial infarction:A report of the american college of cardiology/american heart association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non st-elevation myocardial infarction):Developed in collaboration with the american college of emergency physicians, the society for cardiovascular angiography and interventions, and the society of thoracic surgeons:Endorsed by the american association of cardiovascular and pulmonary rehabilitation and the society for academic emergency medicine [J]. Circulation.2007;116(7):e148-304.
24. 胡盛寿,高润霖,高培显,李立环,熊辉,徐波,杨跃进,袁晋青,郑哲.-站式复合血管重建技术治疗无保护左主干病变[J].中华心血管病杂志.2010；38(1)：23-26.
25. Lopez JJ, Ho KK, Stoler RC, Caputo RP, Carrozza JP, Kuntz RE, Baim DS, Cohen DJ. Percutaneous treatment of protected and unprotected left main coronary stenoses with new devices:Immediate angiographic results and intermediate-term follow-up [J]. J Am Coll Cardiol.1997;29(2):345-352.
26. Miketic S, Carlsson J, Neuhaus KL, Bonzel T, Grube E, Tebbe U. Percutaneous transluminal coronary angioplasty of left main stenosis-results of the german ptca registry [J]. Z Kardiol.2000;89(6):508-512.
27. Kelley MP, Klugherz BD, Hashemi SM, Meneveau NF, Johnston JM, Matthai WH, Jr., Banka VS, Herrmann HC, Hirshfeld JW, Jr., Kimmel SE, Kolansky DM, Horwitz PA, Schiele F, Bassand JP, Wilensky RL. One-year clinical outcomes of protected and unprotected left main coronary artery stenting [J]. Eur Heart J.2003;24(17):1554-1559.
1. Angelini GD, Wilde P, Salerno TA, Bosco G, Calafiore AM. Integrated left small thoracotomy and angioplasty for multivessel coronary artery revascularisation [J]. Lancet.1996;347(9003):757-758.
2. Fonger JD. Integrated myocardial revascularization [J]. Eur J Cardiothorac Surg.1999;16 Suppl 2:S12-17.
3. Friedrich GJ, Bonatti J. Hybrid coronary artery revascularization-review and update 2007 [J]. Heart Surg Forum.2007;10(4):E292-296.
4. Kiaii B, McClure RS, Kostuk WJ, Rayman R, Swinamer S, Dobkowski WB, Novick RJ. Concurrent robotic hybrid revascularization using an enhanced operative suite [J]. Chest.2005;128(6):4046-4048.
5. 胡盛寿.正值“复合”(hybrid)技术的时代[J].中华心血管病杂志.2008；36(1)：1-2.
6. Reicher B, Poston RS, Mehra MR, Joshi A, Odonkor P, Kon Z, Reyes PA, Zimrin DA. Simultaneous "Hybrid" Percutaneous coronary intervention and minimally invasive surgical bypass grafting:Feasibility, safety, and clinical outcomes [J]. Am Heart J.2008;155(4):661-667.
7. Kon ZN, Brown EN, Tran R, Joshi A, Reicher B, Grant MC, Kallam S, Burris N, Connerney I, Zimrin D, Poston RS. Simultaneous hybrid coronary revascularization reduces postoperative morbidity compared with results from conventional off-pump coronary artery bypass [J]. J Thorac Cardiovasc Surg. 2008;135(2):367-375.
8. Kiaii B, McClure RS, Stewart P, Rayman R, Swinamer SA, Suematsu Y, Fox S. Higgins J, Albion C, Kostuk WJ, Almond D, Sridhar K, Teefy P, Jablonsky G, Diamantouros P, Dobkowski WB, Jones P, Bainbridge D, Iglesias I, Murkin J, Cheng D, Novick RJ. Simultaneous integrated coronary artery revascularization with long-term angiographic follow-up [J]. J Thorac Cardiovasc Surg.2008;136(3):702-708.
9. Hu SS. One-stop hybrid approach for cardiovascular disease:From conception to practice [J]. Ann Thorac Cardiovasc Surg.2008;14(6):345-346.
10. Bonatti J, Schachner T, Bonaros N, Jonetzko P, Ohlinger A, Ruetzler E, Kolbitsch C, Feuchtner G, Laufer G, Pachinger O, Friedrich G. Simultaneous hybrid coronary revascularization using totally endoscopic left internal mammary artery bypass grafting and placement of rapamycin eluting stents in the same interventional session. The combination pilot study [J]. Cardiology. 2008;110(2):92-95.
11. 高培显,熊辉,胡盛寿.杂交(hybrid)技术治疗冠状动脉多支病变：进展和争议[J].中华胸心血管外科杂志.2009；25(4)：274-276.
12. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study [J]. Lancet. 2007;369(9562):667-678
13. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, Gick M, Caputo A, Buttner HJ, Neumann FJ. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement [J]. J Am Coll Cardiol. 2006;48(9):1742-1750.
14. Marcucci R, Paniccia R, Antonucci E, Poli S, Gori AM, Valente S, Giglioli C, Lazzeri C, Prisco D, Abbate R, Gensini GF. Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy [J]. Thromb Haemost.2007;98(4):844-851.
15. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, Moschi G, Gori AM, Abbate R, Antoniucci D. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis [J]. J Am Coll Cardiol.2007;49(24):2312-2317.
16. Gurbel PA. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events:Emergence of a new cardiovascular risk factor [J]. Rev Cardiovasc Med.2006;7 Suppl 4:S20-28.
17. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US. Platelet reactivity in patients and recurrent events post-stenting: Results of the prepare post-stenting study [J]. J Am Coll Cardiol. 2005;46(10):1820-1826.
18. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents [J]. N Engl J Med.2007;356(10):1020-1029.
19. Pinto Slottow TL, Waksman R. Overview of the 2006 food and drug administration circulatory system devices panel meeting on drug-eluting stent thrombosis [J]. Catheter Cardiovasc Interv.2007;69(7):1064-1074.
20. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents [J]. JAMA.2005;293(17):2126-2130.
21. Shim JH, Jo WM, Chung WJ, Chung JH. Unexpected stent thrombus after minimally invasive direct coronary artery bypass in hybrid re-vascularisation [J]. Eur J Cardiothorac Surg.2009.
22. Brilakis ES, Banerjee S, Berger PB. Perioperative management of patients with coronary stents [J]. J Am Coll Cardiol.2007;49(22):2145-2150.
23. Sautter RD, Myers WO, Ray JF,3rd, Wenzel FJ. Relationship of fibrinolytic system to postoperative thrombotic phenomena [J]. Arch Surg. 1973;107(2):292-296.
24. Bednar F, Osmancik P, Vanek T, Mocikova H, Jares M, Straka Z, Widimsky P. Platelet activity and aspirin efficacy after off-pump compared with on-pump coronary artery bypass surgery:Results from the prospective randomized trial prague 11-coronary artery bypass and reactivity of thrombocytes (cabaret) [J]. J Thorac Cardiovasc Surg.2008;136(4):1054-1060.
25. Hongo RH, Ley J, Dick SE, Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting [J]. J Am Coll Cardiol.2002;40(2):231-237.
26. Chu MW, Wilson SR, Novick RJ, Stitt LW, Quantz MA. Does clopidogrel increase blood loss following coronary artery bypass surgery? [J]. Ann Thorac Surg.2004;78(5):1536-1541.
27. Byrne JG, Leacche M, Unic D, Rawn JD, Simon DI, Rogers CD, Cohn LH. Staged initial percutaneous coronary intervention followed by valve surgery ("Hybrid approach") for patients with complex coronary and valve disease [J]. J Am Coll Cardiol.2005;45(1):14-18.
28. Byrne JG, Leacche M, Vaughan DE, Zhao DX. Hybrid cardiovascular procedures [J]. JACC Cardiovasc Interv.2008;1(5):459-468.
29. Leong JY, Baker RA, Shah PJ, Cherian VK, Knight JL. Clopidogrel and bleeding after coronary artery bypass graft surgery [J]. Ann Thorac Surg. 2005;80(3):928-933.
30. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting:Response variability, drug resistance, and the effect of pretreatment platelet reactivity [J]. Circulation.2003;107(23):2908-2913.
31. Zhao DX, Leacche M, Balaguer JM, Boudoulas KD, Damp JA, Greelish JP, Byrne JG, Ahmad RM, Ball SK, Cleator JH, Deegan RJ, Eagle SS, Fong PP, Fredi JL, Hoff SJ, Jennings HS,3rd, McPherson JA, Piana RN, Pretorius M, Robbins MA, Slosky DA, Thompson A. Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/operating room [J]. J Am Coll Cardiol.2009;53(3):232-241.
32. Maltais S, Perrault LP, Do QB. Effect of clopidogrel on bleeding and transfusions after off-pump coronary artery bypass graft surgery:Impact of discontinuation prior to surgery [J]. Eur J Cardiothorac Surg. 2008;34(1):127-131.
33. Tschoepe D, Schultheiss HP, Kolarov P, Schwippert B, Dannehl K, Nieuwenhuis HK, Kehrel B, Strauer B, Gries FA. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after ptca [J]. Circulation.1993;88(1):37-42.
34. Gawaz M, Neumann FJ, Ott I, May A, Schomig A. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy [J]. Circulation. 1996;94(3):279-285.
35. Michelson AD. Platelet function testing in cardiovascular diseases [J]. Circulation.2004;110(19):e489-493.
36. Kabbani SS, Watkins MW, Ashikaga T, Terrien EF, Holoch PA, Sobel BE, Schneider DJ. Platelet reactivity characterized prospectively:A determinant of outcome 90 days after percutaneous coronary intervention [J]. Circulation. 2001;104(2):181-186.
37. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation [J]. N Engl J Med.2001;345(7):494-502.
38. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting:The clopidogrel aspirin stent international cooperative study (classics) [J]. Circulation.2000;102(6):624-629.
39. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention:The pci-cure study [J]. Lancet.2001;358(9281):527-533.
40. Steinhubl SR, Berger PB, Mann JT,3rd, Fry ET, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention:A randomized controlled trial [J]. JAMA. 2002;288(19):2411-2420.
41. Gianetti J, Parri MS, Sbrana S, Paoli F, Maffei S, Paradossi U, Berti S, Clerico A, Biagini A. Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty:A 6 months prospective study [J]. Thromb Res.2006;118(4):487-493.
42. Gurbel PA, Cummings CC, Bell CR, Alford AB, Meister AF, Serebruany VL. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting:The plavix reduction of new thrombus occurrence (pronto) trial [J]. Am Heart J.2003;145(2):239-247.
43. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, Bonnet JL, Alessi MC. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome [J]. J Thromb Haemost. 2006;4(3):542-549.
44. L'Allier PL, Ducrocq G, Pranno N, Noble S, Ibrahim R, Gregoire JC, Azzari F, Nozza A, Berry C, Doucet S, Labarthe B, Theroux P, Tardif JC. Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens:Results from the prepair randomized study [J]. J Am Coll Cardiol.2008;51(11):1066-1072.
45. Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, Ormiston J, El-Jack S, Armstrong G, Kay P, Scott D, Gunes A, Dahl ML. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel:The princ (plavix response in coronary intervention) trial [J]. JACC Cardiovasc
Interv.2008;1(6):612-619.
46. Cannon CP, Maraganore JM, Loscalzo J, McAllister A, Eddings K, George D, Selwyn AP, Adelman B, Fox I, Braunwald E, et al. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease [J]. Am J Cardiol.1993;71(10):778-782.
47. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM. Bivalirudin for patients with acute coronary syndromes [J]. N Engl J Med.2006;355(21):2203-2216.
48. Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention:A subgroup analysis from the acute catheterization and urgent intervention triage strategy (acuity) trial [J]. Lancet.2007;369(9565):907-919.
49. Feit F, Manoukian SV, Ebrahimi R, Pollack CV, Ohman EM, Attubato MJ, Mehran R, Stone GW. Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes:A report from the acuity (acute catheterization and urgent intervention triage strategy) trial [J]. J Am Coll Cardiol.2008;51(17):1645-1652.
50. White HD, Chew DP, Hoekstra JW, Miller CD, Pollack CV, Jr., Feit F, Lincoff AM, Bertrand M, Pocock S, Ware J, Ohman EM, Mehran R, Stone GW. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-st-segment elevation acute coronary syndromes managed with an invasive strategy:Results from the acuity (acute catheterization and urgent intervention triage strategy) trial [J]. J Am Coll Cardiol.2008;51(18):1734-1741.
51. Dyke CM, Smedira NG, Koster A, Aronson S, McCarthy HL,2nd, Kirshner R, Lincoff AM, Spiess BD. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass:The evolution-on study [J]. J Thorac Cardiovasc Surg.2006;131(3):533-539.
52. Smedira NG, Dyke CM, Koster A, Jurmann M, Bhatia DS, Hu T, McCarthy HL,2nd, Lincoff AM, Spiess BD, Aronson S. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting:The results of the evolution-off study [J]. J Thorac Cardiovasc Surg.2006;131(3):686-692.
53. Palmer GJ, Sankaran IS, Sparkman GM, Koster A, Dyke CM, Ebra G. Routine use of the direct thrombin inhibitor bivalirudin for off-pump coronary artery bypass grafting is safe and effective [J]. Heart Surg Forum. 2008; 11(1):E24-29.
54. Murphy GS, Marymont JH. Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery [J]. J Cardiothorac Vasc Anesth.2007;21(1):113-126.
55. Schuhlen H, Kastrati A, Pache J, Dirschinger J, Schomig A. Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement:Analysis of 5,678 patients with a four-week ticlopidine regimen [J]. J Am Coll Cardiol.2001;37(8):2066-2073.
56. Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, Seth A, Sousa JE, Wijns W, Berge C, Deme M, Stoll HP. Safety of coronary sirolimus-eluting stents in daily clinical practice:One-year follow-up of the e-cypher registry [J]. Circulation.2006;113(11):1434-1441.
57. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent anticoagulation restenosis study investigators [J]. N Engl J Med.1998;339(23):1665-1671.
58. Harrison P, Frelinger AL,3rd, Furman MI, Michelson AD. Measuring antiplatelet drug effects in the laboratory [J]. Thromb Res. 2007;120(3):323-336.
1. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, Davis K, Killip T, Passamani E, Norris R, et al. Effect of coronary artery bypass graft surgery on survival:Overview of 10-year results from randomised trials by the coronary artery bypass graft surgery trialists collaboration [J]. Lancet. 1994;344(8922):563-570.
2. De Maria R, Repossini A, Dabdoob W, Parolini M, Cianci V, Bestetti A, Binetti G, Arena V, Parodi O. Myocardial perfusion imaging evidence of functionally complete revascularization by minimally invasive direct coronary artery bypass in 2-vessel coronary artery disease [J]. J Nucl Cardiol.2007;14(6):860-868.
3. Kim KB, Cho KR, Jeong DS. Midterm angiographic follow-up after off-pump coronary artery bypass:Serial comparison using early,1-year, and 5-year postoperative angiograms [J]. J Thorac Cardiovasc Surg.2008;135(2):300-307.
4. Goldman S, Zadina K, Moritz T, Ovitt T, Sethi G, Copeland JG, Thottapurathu L, Krasnicka B, Ellis N, Anderson RJ, Henderson W. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery:Results from a department of veterans affairs cooperative study [J]. J Am Coll Cardiol.2004;44(11):2149-2156.
5. Loop FD, Lytle BW, Cosgrove DM, Stewart RW, Goormastic M, Williams GW, Golding LA, Gill CC, Taylor PC, Sheldon WC, et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events [J]. N Engl J Med.1986;314(1):1-6.
6. Tatoulis J, Buxton BF, Fuller JA. Patencies of 2127 arterial to coronary conduits over 15 years [J]. Ann Thorac Surg.2004;77(1):93-101.
7. Sabik JF,3rd, Lytle BW, Blackstone EH, Houghtaling PL, Cosgrove DM. Comparison of saphenous vein and internal thoracic artery graft patency by coronary system [J]. Ann Thorac Surg.2005;79(2):544-551; discussion 544-551.
8. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome:Angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years [J]. J Am Coll Cardiol.1996;28(3):616-626.
9. Hannan EL, Wu C, Walford G, Culliford AT, Gold JP, Smith CR, Higgins RS, Carlson RE, Jones RH. Drug-eluting stents vs. Coronary-artery bypass grafting in multivessel coronary disease [J]. N Engl J Med.2008;358(4):331-341.
10. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB. Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents [J]. N Engl J Med.2007;356(10):998-1008.
11. Roiron C, Sanchez P, Bouzamondo A, Lechat P, Montalescot G. Drug eluting stents:An updated meta-analysis of randomised controlled trials [J]. Heart. 2006;92(5):641-649.
12. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery [J]. N Engl J Med.2003;349(14):1315-1323.
13. Meliga E, Garcia-Garcia HM, Kukreja N, Daemen J, Tanimoto S, Ramcharitar S, van Mieghem CA, Sianos G, van der Ent M, van der Giessen WJ, de Feyter P, van Domburg R, Serruys PW. Chronic total occlusion treatment in post-cabg patients: Saphenous vein graft versus native vessel recanalization-long-term follow-up in the drug-eluting stent era [J]. Catheter Cardiovasc Interv.2007;70(1):21-25.
14. 胡盛寿.正值“复合”(hybrid)技术的时代[J].中华心血管病杂志.2008；36(1)：1-2.
15. Angelini GD, Wilde P, Salerno TA, Bosco G, Calafiore AM. Integrated left small thoracotomy and angioplasty for multivessel coronary artery revascularisation [J]. Lancet.1996;347(9003):757-758.
16. Kon ZN, Brown EN, Tran R, Joshi A, Reicher B, Grant MC, Kallam S, Burris N, Connerney I, Zimrin D, Poston RS. Simultaneous hybrid coronary revascularization reduces postoperative morbidity compared with results from conventional off-pump coronary artery bypass [J]. J Thorac Cardiovasc Surg. 2008;135(2):367-375.
17. Katz MR, Van Praet F, de Canniere D, Murphy D, Siwek L, Seshadri-Kreaden U, Friedrich G, Bonatti J. Integrated coronary revascularization:Percutaneous coronary intervention plus robotic totally endoscopic coronary artery bypass [J]. Circulation.2006; 114(1 Suppl):I473-476.
18. Reicher B, Poston RS, Mehra MR, Joshi A, Odonkor P, Kon Z, Reyes PA, Zimrin DA. Simultaneous "Hybrid" Percutaneous coronary intervention and minimally invasive surgical bypass grafting:Feasibility, safety, and clinical outcomes [J]. Am Heart J.2008;155(4):661-667.
19. Davidavicius G, Van Praet F, Mansour S, Casselman F, Bartunek J, Degrieck I, Wellens F, De Geest R, Vanermen H, Wijns W, De Bruyne B. Hybrid revascularization strategy:A pilot study on the association of robotically enhanced minimally invasive direct coronary artery bypass surgery and fractional-flow-reserve-guided percutaneous coronary intervention [J]. Circulation.2005; 112(9 Suppl):I317-322.
20. 郑哲,胡盛寿,周玉燕.电视胸腔镜辅助下微创冠状动脉旁路移植术临床及随访结果[J].中华胸心血管外科杂志.2006；22(1)：52-53.
21. 胡盛寿,高润霖,郑哲,徐波.Hybrid技术治疗多支病变冠状动脉粥样硬化性心脏病[J].中国胸心血管外科临床杂志.2000；7(4)：273-274.
22. 赵强,夏利民,陈安清,王哲,徐德民.杂交技术在冠状动脉外科中的应用[J].中国微创外科杂志.2006；6(6)：421-423.
23. 王东进,邵峻,梁雨露,武忠,潘俊.胸腔镜辅助下冠状动脉旁路移植术与介入联合治疗冠心病多支病变七例 [J].中华心血管病杂志2006；34(3)：247-248.
24. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB, Jr., Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT. Efficacy and safety of edifoligide, an e2f transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: Prevent iv:A randomized controlled trial [J]. JAMA.2005;294(19):2446-2454.
25. Zhao DX, Leacche M, Balaguer JM, Boudoulas KD, Damp JA, Greelish JP, Byrne JG, Ahmad RM, Ball SK, Cleator JH, Deegan RJ, Eagle SS, Fong PP, Fredi JL, Hoff SJ, Jennings HS,3rd, McPherson JA, Piana RN, Pretorius M, Robbins MA, Slosky DA, Thompson A. Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/operating room [J]. J Am Coll Cardiol.2009;53(3):232-241.
26. Riess FC, Schofer J, Kremer P, Riess AG, Bergmann H, Moshar S, Mathey D, Bleese N. Beating heart operations including hybrid revascularization:Initial experiences [J]. Ann Thorac Surg.1998;66(3):1076-1081.
27. Byrne JG, Leacche M, Vaughan DE, Zhao DX. Hybrid cardiovascular procedures [J]. JACC Cardiovasc Interv.2008;1l(5):459-468.
28. Lloyd CT, Calafiore AM, Wilde P, Ascione R, Paloscia L, Monk CR, Angelini GD. Integrated left anterior small thoracotomy and angioplasty for coronary artery revascularization [J]. Ann Thorac Surg.1999;68(3):908-911; discussion 911-902.
29. Isomura T, Suma H, Horii T, Sato T, Kobashi T, Kanemitsu H. Minimally invasive coronary artery revascularization:Off-pump bypass grafting and the hybrid procedure [J]. Ann Thorac Surg.2000;70(6):2017-2022.
30. de Canniere D, Jansens JL, Goldschmidt-Clermont P, Barvais L, Decroly P, Stoupel E. Combination of minimally invasive coronary bypass and percutaneous transluminal coronary angioplasty in the treatment of double-vessel coronary disease:Two-year follow-up of a new hybrid procedure compared with “On-pump” Double bypass grafting [J]. Am Heart J.2001;142(4):563-570.
31. Presbitero P, Nicolini F, Maiello L, Franciosi G, Carcagni A, Milone F, Manasse E, Gallotti R. "Hybrid" Percutaneous and surgical coronary revascularization: Selection criteria from a single-center experience [J]. Ital Heart J. 2001;2(5):363-368.
32. Cisowski M, Morawski W, Drzewiecki J, Kruczak W, Toczek K, Bis J, Bochenek A. Integrated minimally invasive direct coronary artery bypass grafting and angioplasty for coronary artery revascularization [J]. Eur J Cardiothorac Surg. 2002;22(2):261-265.
33. Stahl KD, Boyd WD, Vassiliades TA, Karamanoukian HL. Hybrid robotic coronary artery surgery and angioplasty in multivessel coronary artery disease [J]. Ann Thorac Surg.2002;74(4):S1358-1362.
34. Lewis BS, Porat E, Halon DA, Ammar R, Flugelman MY, Khader N, Merdler A, Weisz G, Uretzky G Same-day combined coronary angioplasty and minimally invasive coronary surgery [J]. Am J Cardiol.1999;84(10):1246-1247, A1248.
35. Wittwer T, Cremer J, Klima U, Wahlers T, Haverich A. Myocardial "Hybrid" Revascularization:Intermediate results of an alternative approach to multivessel coronary artery disease [J]. J Thorac Cardiovasc Surg.1999; 118(4):766-767.
36. Riess FC, Bader R, Kremer P, Kuhn C, Kormann J, Mathey D, Moshar S, Tuebler T, Bleese N, Schofer J. Coronary hybrid revascularization from January 1997 to January 2001:A clinical follow-up [J]. Ann Thorac Surg.2002;73(6):1849-1855.
37. Zenati M, Cohen HA, Griffith BP. Alternative approach to multivessel coronary disease with integrated coronary revascularization [J]. J Thorac Cardiovasc Surg. 1999;117(3):439-444; discussion 444-436.
38. Us MH, Basaran M, Yilmaz M, Yaymaci B, Ulusoy E, Sanioglu S, Ozbek C, Arslan Y, Pocan S, Yilmaz AT. Hybrid coronary revascularization in high-risk patients [J]. Tex Heart Inst J.2006;33(4):458-462.
39. Gilard M, Bezon E, Cornily JC, Mansourati J, Mondine P, Barra JA, Boschat J. Same-day combined percutaneous coronary intervention and coronary artery surgery [J]. Cardiology.2007;108(4):363-367.
40. Lee MS, Wilentz JR, Makkar RR, Singh V, Nero T, Swistel D, Belsey SJ, Simon C, Rametta S, DeRose J. Hybrid revascularization using percutaneous coronary intervention and robotically assisted minimally invasive direct coronary artery bypass surgery [J]. J Invasive Cardiol.2004; 16(8):419-425.
41. Kiaii B, McClure RS, Kostuk WJ, Rayman R, Swinamer S, Dobkowski WB, Novick RJ. Concurrent robotic hybrid revascularization using an enhanced operative suite [J]. Chest.2005;128(6):4046-4048.
42. Vassiliades TA, Jr., Douglas JS, Morris DC, Block PC, Ghazzal Z, Rab ST, Cates CU. Integrated coronary revascularization with drug-eluting stents:Immediate and seven-month outcome [J]. J Thorac Cardiovasc Surg.2006;131(5):956-962.
43. Bonatti J, Schachner T, Bonaros N, Jonetzko P, Ohlinger A, Ruetzler E, Kolbitsch C, Feuchtner G, Laufer G, Pachinger O, Friedrich G. Simultaneous hybrid coronary revascularization using totally endoscopic left internal mammary artery bypass grafting and placement of rapamycin eluting stents in the same interventional session. The combination pilot study [J]. Cardiology. 2007;110(2):92-95.
44. Kiaii B, McClure RS, Stewart P, Rayman R, Swinamer SA, Suematsu Y, Fox S, Higgins J, Albion C, Kostuk WJ, Almond D, Sridhar K, Teefy P, Jablonsky G, Diamantouros P, Dobkowski WB, Jones P, Bainbridge D, Iglesias I, Murkin J, Cheng D, Novick RJ. Simultaneous integrated coronary artery revascularization with long-term angiographic follow-up [J]. J Thorac Cardiovasc Surg. 2008;136(3):702-708.
45. Gao C, Yang M, Wu Y, Wang G, Xiao C, Liu H, Lu C. Hybrid coronary revascularization by endoscopic robotic coronary artery bypass grafting on beating heart and stent placement [J]. Ann Thorac Surg.2009;87(3):737-741.
46. Fonger JD. Integrated myocardial revascularization [J]. Eur J Cardiothorac Surg. 1999;16 Suppl 2:S12-17.
47. 郑哲,胡盛寿,宋云虎,孙寒松,王水云,蒋世良,徐仲英.杂交(hybrid)手术治疗冠心病多支病变合并房间隔缺损[J].中国微创外科杂志2005；5(12)：978-979.
48. Cohen HA, Zenati M, Smith AJ, Lee JS, Chough S, Jafar Z, Counihan P, Izzo M, Burchenal JE, Feldman AM, Griffith B. Feasibility of combined percutaneous transluminal angioplasty and minimally invasive direct coronary artery bypass in patients with multivessel coronary artery disease [J]. Circulation. 1998;98(11):1048-1050.
49. Wittwer T, Cremer J, Boonstra P, Grandjean J, Mariani M, Mugge A, Drexler H, den Heijer P, Leitner ER, Hepp A, Wehr M, Haverich A. Myocardial "Hybrid" Revascularisation with minimally invasive direct coronary artery bypass grafting combined with coronary angioplasty:Preliminary results of a multicentre study [J]. Heart.2000;83(1):58-63.
50. Hu SS, Gao RL, Gao PX, Li LH, Xiong H, Xu B, Yang YJ, Yuan JQ, Zheng Z. [efficacy of one-stop hybrid revascularization for treatment of unprotected left main coronary artery disease.] [J]. Zhonghua Xin Xue Guan Bing Za Zhi. 2010;38(1):23-26.
51. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Jr., Chavey WE,2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC, Jr., Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B. Acc/aha 2007 guidelines for the management of patients with unstable angina/non-st-elevation myocardial infarction:A report of the american college of cardiology/american heart association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-st-elevation myocardial infarction) developed in collaboration with the american college of emergency physicians, the society for cardiovascular angiography and interventions, and the society of thoracic surgeons endorsed by the american association of cardiovascular and pulmonary rehabilitation and the society for academic emergency medicine [J]. J Am Coll Cardiol.2007;50(7):el-e157.
52. Murphy GJ, Bryan AJ, Angelini GD. Hybrid coronary revascularization in the era of drug-eluting stents [J]. Ann Thorac Surg.2004;78(5):1861-1867.
53. Gao P, Xiong H, Zheng Z, Li L, Gao R, Hu SS. Evaluation of antiplatelet effects of a modified protocol by platelet aggregation in patients undergoing "One-stop" Hybrid coronary revascularization [J]. Platelets.2010;21(3):183-190.
54. 徐仲英,胡海波,黄连军,赵世华,凌坚,郑宏,蒋世良,沈向东.介入技术与外科手术联合治疗复杂先天性心脏病的临床研究[J].中华心血管病杂志.2004；32(2)：144-147.
55. 胡盛寿,李守军,张浩,孙寒松,沈向东,王浩,蒋世良.杂交(hybrid)手术在复杂性先天性心脏病治疗中的初步应用[J].中国微创外科杂志.2005；5(12)：976-977.
56. 胡盛寿,李守军,张浩,王旭,王浩,晏馥霞,蒋世良,李永清.“杂交’’技术治疗新生儿室间隔完整的肺动脉闭锁[J].中华胸心血管外科杂志.2006；22(6)：376-377.
57. Zhang H, Li SJ, Li YQ, Wang H, Hu SS. Hybrid procedure for the neonatal management of pulmonary atresia with intact ventricular septum [J]. J Thorac Cardiovasc Surg.2007;133(6):1654-1656.
58. 李守军,胡盛寿,张浩,沈向东,闫军,王旭,徐仲英,邓喜成,李永青.一站式“杂交”技术治疗婴幼儿先天性心脏病[J].中华心血管病杂志.2009；37(11)：986-989.
59. 郑哲,李守军,胡盛寿,王德,刘志刚,张瑛,徐仲英,胡海波.分期和“一站式"hybrid手术治疗法洛四联症合并体肺动脉侧支血管形成的疗效对比[J].中国胸心血管外科临床杂志.2009；16(4)：250-253.
60. 曾筝,张戈军,蒋世良,黄连军,崔炜,张岩,张少雄,鲍菲,戴汝平.体肺侧枝血管栓塞术在复杂先天性心脏病治疗中的作用[J].中华放射学杂志.1998；32(8)：519-521.
61. 方敏华,朱洪玉,汪曾炜,张仁福,王辉山,李新民.法洛四联症合并大的体肺侧枝动脉手术矫治[J].中华外科杂志.2005；43(22)：1437—1440.
62. 王树水,张智伟,庄建,陈欣欣,钱明阳,李渝芬.心脏外科手术与介入性心导管术镶嵌治疗小儿先天性心脏病[J].中华胸心血管外科杂志.2005；21(2)：82-84.
63. Fishberger SB, Bridges ND, Keane JF, Hanley FL, Jonas RA, Mayer JE, Castaneda AR, Lock JE. Intraoperative device closure of ventricular septal defects [J]. Circulation.1993;88(5 Pt 2):Ⅱ 205-209.
64. Okubo M, Benson LN, Nykanen D, Azakie A, Van Arsdell G, Coles J, Williams WG. Outcomes of intraoperative device closure of muscular ventricular septal defects [J]. Ann Thorac Surg.2001;72(2):416-423.
65. Bacha EA, Cao QL, Galantowicz ME, Cheatham JP, Fleishman CE, Weinstein SW, Becker PA, Hill SL, Koenig P, Alboliras E, Abdulla R, Starr JP, Hijazi ZM. Multicenter experience with perventricular device closure of muscular ventricular septal defects [J]. Pediatr Cardiol.2005;26(2):169-175.
66. Amin Z, Berry JM, Foker JE, Rocchini AP, Bass JL. Intraoperative closure of muscular ventricular septal defect in a canine model and application of the technique in a baby [J]. J Thorac Cardiovasc Surg.1998;115(6):1374-1376.
67. 李巅远,闫军,李守军,晏馥霞,李立环,魏以帧,郑哲,刘志刚,崔彬,陶天富,胡盛寿.三种不同微创技术与经典外科技术治疗房间隔缺损的临床对比 研究[J].中国胸心血管外科临床杂志.2009；16(1)：31-35.
68. 胡海波,凌坚,张戈军,蒋世良,郑宏,徐仲英,赵世华,黄连军,王云.法乐四联症外科根治术后残余右室流出道梗阻的介入治疗[J].中华分子心脏病学杂志.2008；8(4)：231-232.
69. Holzer RJ, Sisk M, Chisolm JL, Hill SL, Olshove V, Phillips A, Cheatham JP, Galantowicz M. Completion angiography after cardiac surgery for congenital heart disease:Complementing the intraoperative imaging modalities [J]. Pediatr Cardiol.2009;30(8):1075-1082.
70. Dake MD, Miller DC, Semba CP, Mitchell RS, Walker PJ, Liddell RP. Transluminal placement of endovascular stent-grafts for the treatment of descending thoracic aortic aneurysms [J]. N Engl J Med. 1994;331(26):1729-1734.
71. Xydas S, Wei B, Takayama H, Russo M, Bacchetta M, Smith CR, Stewart A. Use of carotid-subclavian arterial bypass and thoracic endovascular aortic repair to minimize cerebral ischemia in total aortic arch reconstruction [J]. J Thorac Cardiovasc Surg.2010;139(3):717-722; discussion 722.
72. Ucak A, Onan B, Inan BK, Temizkan V, Ugur M, Yilmaz AT. Hybrid repair of an acute type b dissection with subclavian-to-subclavian bypass and stent-grafting [J]. J Card Surg.2010
73. Patel HJ, Upchurch GR, Jr., Eliason JL, Criado E, Rectenwald J, Williams DM, Deeb GM. Hybrid debranching with endovascular repair for thoracoabdominal aneurysms:A comparison with open repair [J]. Ann Thorac Surg. 2010;89(5):1475-1481.
74. Donas KP, Lachat M, Rancic Z, Oberkofler C, Pfammatter T, Guber I, Veith FJ, Mayer D. Early and midterm outcome of a novel technique to simplify the hybrid procedures in the treatment of thoracoabdominal and pararenal aortic aneurysms [J]. J Vasc Surg.2009;50(6):1280-1284.
75. Bockler D, Nassar J, Kotelis D, Geisbusch P, Hyhlik-Durr A, Von Tengg-Kobligk H, Weber TF, Schumacher H. Hybrid approach for arch and thoracoabdominal pathologies [J]. J Cardiovasc Surg (Torino).2009;50(4):461-474.
76. Black SA, Wolfe JH, Clark M, Hamady M, Cheshire NJ, Jenkins MP. Complex thoracoabdominal aortic aneurysms:Endovascular exclusion with visceral revascularization [J]. J Vasc Surg.2006;43(6):1081-1089; discussion 1089.
77. Biasi L, Ali T, Loosemore T, Morgan R, Loftus I, Thompson M. Hybrid repair of complex thoracoabdominal aortic aneurysms using applied endovascular strategies combined with visceral and renal revascularization [J]. J Thorac Cardiovasc Surg.2009;138(6):1331-1338.
78. Patel R, Conrad MF, Paruchuri V, Kwolek CJ, Chung TK, Cambria RP. Thoracoabdominal aneurysm repair:Hybrid versus open repair [J]. J Vasc Surg. 2009;50(1):15-22.
79. Kato M, Ohnishi K, Kaneko M, Ueda T, Kishi D, Mizushima T, Matsuda H. New graft-implanting method for thoracic aortic aneurysm or dissection with a stented graft [J]. Circulation.1996;94(9 Suppl):Ⅱ 188-193.
80. Brueck M, Heidt MC, Szente-Varga M, Bandorski D, Kramer W, Vogt PR. Hybrid treatment for complex aortic problems combining surgery and stenting in the integrated operating theater [J]. J Interv Cardiol.2006;19(6):539-543.
81. 田川,常谦,孙立忠,于存涛,郑军,朱俊明,刘永民,董超.应用象鼻技术治疗主动脉夹层和主动脉瘤 [J].中华胸心血管外科杂志2007；23(3)：178-180.
82. Cox JL. The surgical treatment of atrial fibrillation. Iv. Surgical technique [J]. J Thorac Cardiovasc Surg.1991;101(4):584-592.
83. Ad N. The cox-maze procedure:History, results, and predictors for failure [J]. J Interv Card Electrophysiol.2007;20(3):65-71.
84. Choi JI, Pak HN, Kim YH. Hybrid epicardial and endocardial catheter ablation in a patient with atrial fibrillation and suspicious left atrial thrombus [J]. Circ J. 2009;73(2):384-387.
85. Machino T, Tada H, Sekiguchi Y, Tanaka Y, Naito S, Yamasaki H, Arimoto T, Igarashi M, Kuroki K, Seo Y, Watanabe S, Hoshizaki H, Oshima S, Taniguchi K, Aonuma K. Hybrid therapy of radiofrequency catheter ablation and percutaneous transvenous mitral commissurotomy in patients with atrial fibrillation and mitral stenosis [J]. J Cardiovasc Electrophysiol.2009
86. Skanes AC, Klein GJ, Guiraudon G, Menkis AH, Jones DL, Krahn AD, Yee R. Hybrid approach for minimally-invasive operative therapy of arrhythmias [J]. J Interv Card Electrophysiol.2003;9(2):289-294.
87. Borger MA, Fremes SE, Weisel RD, Cohen G, Rao V, Lindsay TF, Naylor CD. Coronary bypass and carotid endarterectomy:Does a combined approach increase risk? Ametaanalysis [J]. Ann Thorac Surg.1999;68(1):14-20; discussion 21.
88. Salasidis GC, Latter DA, Steinmetz OK, Blair JF, Graham AM. Carotid artery duplex scanning in preoperative assessment for coronary artery revascularization: The association between peripheral vascular disease, carotid artery stenosis, and stroke [J]. J Vasc Surg.1995;21(1):154-160; discussion 161-152.
89. Das SK, Brow TD, Pepper J. Continuing controversy in the management of concomitant coronary and carotid disease:An overview [J]. Int J Cardiol. 2000;74(1):47-65.
90. Mathias KD. Angioplasty and stenting for carotid lesions:An argument for [J]. Adv Surg.1999;32:225-243.
91. Lopes DK, Mericle RA, Lanzino Q Wakhloo AK, Guterman LR, Hopkins LN. Stent placement for the treatment of occlusive atherosclerotic carotid artery disease in patients with concomitant coronary artery disease [J]. J Neurosurg. 2002;96(3):490-496.
92. Versaci F, Del Giudice C, Scafuri A, Zeitani J, Gandini R, Nardi P, Salvati A, Pampana E, Sebastiano F, Romagnoli A, Simonetti G, Chiariello L. Sequential hybrid carotid and coronary artery revascularization:Immediate and mid-term results [J]. Ann Thorac Surg.2007;84(5):1508-1513; discussion 1513-1504.
93. Masroor S, Berkowitz R, Nejad K, Alexander JC. Hybrid percutaneous coronary intervention and minimally invasive reoperative mitral valve surgery [J]. J Card Surg.2009;24(2):191-193.
94. Byrne JG, Leacche M, Unic D, Rawn JD, Simon DI, Rogers CD, Cohn LH. Staged initial percutaneous coronary intervention followed by valve surgery ("Hybrid approach") for patients with complex coronary and valve disease [J]. J Am Coll Cardiol.2005;45(1):14-18.